|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
CA2872136C
(en)
|
2002-07-18 |
2017-06-20 |
Merus B.V. |
Recombinant production of mixtures of antibodies
|
|
AU2004242614B2
(en)
|
2003-05-30 |
2011-09-22 |
Merus N.V. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2006106905A1
(en)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
JP5144499B2
(en)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
Antibody modification method for purifying bispecific antibodies
|
|
DK2006381T3
(en)
|
2006-03-31 |
2016-02-22 |
Chugai Pharmaceutical Co Ltd |
PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
|
|
AU2007305443B2
(en)
|
2006-09-29 |
2012-08-23 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
WO2008076904A1
(en)
|
2006-12-14 |
2008-06-26 |
Aileron Therapeutics, Inc. |
Bis-sulfhydryl macrocyclization systems
|
|
EP2564862B1
(en)
|
2007-02-23 |
2017-08-02 |
Aileron Therapeutics, Inc. |
Substituted amino acids for preparing triazole linked macrocyclic peptides
|
|
ES2430067T3
(en)
|
2007-03-28 |
2013-11-18 |
President And Fellows Of Harvard College |
Sewn polypeptides
|
|
MX2009010282A
(en)
|
2007-03-29 |
2009-10-12 |
Genmab As |
Bispecific antibodies and methods for production thereof.
|
|
ES2566957T3
(en)
|
2007-09-26 |
2016-04-18 |
Chugai Seiyaku Kabushiki Kaisha |
Constant region of modified antibody
|
|
DK2202245T3
(en)
|
2007-09-26 |
2016-11-21 |
Chugai Pharmaceutical Co Ltd |
A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
SI2235064T1
(en)
*
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
CN102076355B
(en)
|
2008-04-29 |
2014-05-07 |
Abbvie公司 |
Dual varistructure domain immunoglobulins and uses thereof
|
|
TW201008580A
(en)
|
2008-06-03 |
2010-03-01 |
Abbott Lab |
Dual variable domain immunoglobulin and uses thereof
|
|
KR20220002710A
(en)
|
2008-06-26 |
2022-01-06 |
악셀레론 파마 인코포레이티드 |
Methods for dosing an activin-actriia antagonist and monitoring of treated patients
|
|
JP5674654B2
(en)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
Prostaglandin E2 double variable domain immunoglobulin and use thereof
|
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
|
BRPI1006139A2
(en)
|
2009-01-14 |
2017-05-30 |
Aileron Therapeutics Inc |
peptidomimetic macrocycles
|
|
EP2382228B2
(en)
|
2009-01-21 |
2026-01-07 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
WO2010084197A1
(en)
*
|
2009-01-26 |
2010-07-29 |
Genmab A/S |
Methods for producing mixtures of antibodies
|
|
TWI682995B
(en)
|
2009-03-19 |
2020-01-21 |
日商中外製藥股份有限公司 |
Antibody constant region alteration
|
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
CN102365297B
(en)
|
2009-03-25 |
2014-10-29 |
霍夫曼-拉罗奇有限公司 |
Novel anti-α5β1 antibody and its application
|
|
JP5616428B2
(en)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
Trivalent bispecific antibody
|
|
AU2013203859B2
(en)
*
|
2009-04-27 |
2016-09-08 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
WO2010129304A2
(en)
*
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
CA2766220C
(en)
|
2009-06-26 |
2021-02-09 |
Regeneron Pharmaceuticals, Inc. |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
AU2010270844A1
(en)
|
2009-07-08 |
2011-12-22 |
Amgen Inc. |
Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering
|
|
UY32808A
(en)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
IMMUNOGLOBULINS AS A DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
|
WO2011028952A1
(en)
*
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CA2781519A1
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
CN102712675A
(en)
|
2009-09-22 |
2012-10-03 |
爱勒让治疗公司 |
Peptidomimetic macrocycles
|
|
JP5837821B2
(en)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
Antibody constant region variants
|
|
BR112012008833A2
(en)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
double variable domain immunoglobulins and uses thereof
|
|
EP3072526B1
(en)
|
2009-10-16 |
2018-09-26 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
UY32979A
(en)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
|
CA2781539C
(en)
|
2009-11-23 |
2021-07-20 |
Amgen Inc. |
Monomeric antibody fc
|
|
HUE029257T2
(en)
*
|
2009-12-29 |
2017-02-28 |
Aptevo Res And Dev Llc |
Heterodimer binding proteins and uses thereof
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
PL2505654T5
(en)
|
2010-02-08 |
2020-11-30 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
CN102892779B
(en)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
Neuregulin antagonist and the purposes in treatment cancer thereof
|
|
WO2011108714A1
(en)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
Antibody constant region variant
|
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
WO2011127418A1
(en)
|
2010-04-09 |
2011-10-13 |
Amgen Inc. |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
|
AU2013203221B2
(en)
*
|
2010-04-20 |
2016-06-02 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
JP2019048814A
(en)
*
|
2010-04-20 |
2019-03-28 |
ゲンマブ エー／エス |
Heterodimeric antibody Fc-containing protein and method for producing the same
|
|
AU2016219622A1
(en)
*
|
2010-04-20 |
2016-09-15 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
ES2989108T3
(en)
*
|
2010-04-20 |
2024-11-25 |
Genmab As |
Proteins containing heterodimeric antibody FC and methods for producing the same
|
|
TW201742925A
(en)
|
2010-04-23 |
2017-12-16 |
建南德克公司 |
Production of heteromultimeric proteins
|
|
US9527926B2
(en)
*
|
2010-05-14 |
2016-12-27 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CA2800785C
(en)
|
2010-05-27 |
2019-09-24 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
BR112012027995A2
(en)
|
2010-06-18 |
2017-01-10 |
Genentech Inc |
antibody and isolated nucleic acid, host cell, method of producing an antibody, immunoconjugate, pharmaceutical formulation, use of the antibody, method of treating an individual with cancer, an individual having an immune disorder, inhibiting angiogenesis and inhibiting the constitutive activation of axl
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
JP2013539962A
(en)
|
2010-07-09 |
2013-10-31 |
ジェネンテック， インコーポレイテッド |
Anti-neuropilin antibodies and methods of use
|
|
CN103180737A
(en)
|
2010-07-19 |
2013-06-26 |
霍夫曼-拉罗奇有限公司 |
Method of identifying patients with increased likelihood of responding to anticancer therapy
|
|
WO2012010549A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
RU2013106216A
(en)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
BIOMARKERS OF CHRONIC Lymphocytic Leukemia
|
|
PE20131412A1
(en)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
|
EP2600898A1
(en)
|
2010-08-05 |
2013-06-12 |
F.Hoffmann-La Roche Ag |
Anti-mhc antibody anti-viral cytokine fusion protein
|
|
CN103168049B
(en)
|
2010-08-13 |
2015-10-07 |
罗切格利卡特公司 |
Anti-tenascin-C A2 antibody and using method
|
|
KR101780131B1
(en)
|
2010-08-13 |
2017-09-19 |
로슈 글리카트 아게 |
Anti-fap antibodies and methods of use
|
|
DK2603600T3
(en)
|
2010-08-13 |
2019-03-04 |
Aileron Therapeutics Inc |
PEPTIDOMIMETIC MACROCYCLES
|
|
CN103080132B
(en)
|
2010-08-25 |
2016-06-08 |
弗·哈夫曼-拉罗切有限公司 |
Antibodies against IL-18R1 and uses thereof
|
|
EP2608803A4
(en)
|
2010-08-26 |
2014-01-15 |
Abbvie Inc |
Dual variable domain immunoglobulins and uses thereof
|
|
RU2013114360A
(en)
|
2010-08-31 |
2014-10-10 |
Дженентек, Инк. |
BIOMARKERS AND TREATMENT METHODS
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
AU2011325833C1
(en)
*
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
EP3176184B1
(en)
|
2010-11-10 |
2020-02-19 |
F. Hoffmann-La Roche AG |
Anti-bace1 antibodies for neural disease immunotherapy
|
|
PH12013500974A1
(en)
|
2010-11-17 |
2013-07-08 |
Chugai Pharmaceutical Co Ltd |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
EA034333B1
(en)
|
2010-11-30 |
2020-01-29 |
Дженентек, Инк. |
Variants of an antibody for transporting a compound across the blood-brain barrier
|
|
MX349057B
(en)
|
2010-11-30 |
2017-07-07 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT THAT INDUCES CYTOTOXICITY.
|
|
TWI732259B
(en)
|
2010-12-16 |
2021-07-01 |
美商建南德克公司 |
Diagnosis and treatments relating to th2 inhibition
|
|
WO2012087962A2
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
SG191219A1
(en)
|
2010-12-22 |
2013-07-31 |
Genentech Inc |
Anti-pcsk9 antibodies and methods of use
|
|
KR101913448B1
(en)
|
2011-02-04 |
2018-10-30 |
제넨테크, 인크. |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
TWI666027B
(en)
|
2011-02-10 |
2019-07-21 |
羅齊克雷雅公司 |
Mutant interleukin-2 polypeptides
|
|
WO2012116927A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
|
MX341921B
(en)
|
2011-02-28 |
2016-09-07 |
Hoffmann La Roche |
Antigen binding proteins.
|
|
ES2676878T3
(en)
|
2011-03-03 |
2018-07-25 |
Zymeworks Inc. |
Multivalent heteromultimer frame design and constructs
|
|
CA2830254C
(en)
|
2011-03-16 |
2019-09-10 |
Amgen Inc. |
Fc variants
|
|
EP2688909A2
(en)
|
2011-03-25 |
2014-01-29 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
|
KR101614195B1
(en)
|
2011-03-29 |
2016-04-20 |
로슈 글리카트 아게 |
Antibody fc variants
|
|
MX342240B
(en)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anti-fgfr4 antibodies and methods of use.
|
|
US10752664B2
(en)
|
2011-04-08 |
2020-08-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
|
DK2697257T3
(en)
|
2011-04-13 |
2017-01-30 |
Bristol Myers Squibb Co |
FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
|
|
WO2012143523A1
(en)
*
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
EP2699260B1
(en)
|
2011-04-20 |
2024-11-20 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
CA2832389A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
RU2013150331A
(en)
|
2011-04-20 |
2015-05-27 |
Рош Гликарт Аг |
METHOD AND DEVICES FOR A pH-DEPENDENT PASSAGE OF A HEMATOENCEPHALIC BARRIER
|
|
EA201892619A1
(en)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
|
|
ES2567276T3
(en)
|
2011-05-12 |
2016-04-21 |
Genentech, Inc. |
LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides
|
|
BR112013026266A2
(en)
|
2011-05-16 |
2020-11-10 |
Genentech, Inc |
treatment method, isolated and anti-fgfr1 antibodies, isolated nucleic acid, host cell, method of producing an antibody, pharmaceutical formulation, use of the antibody and method of treating diabetes in an individual
|
|
WO2012171996A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
|
KR20140045440A
(en)
|
2011-06-30 |
2014-04-16 |
제넨테크, 인크. |
Anti-c-met antibody formulations
|
|
RU2641256C2
(en)
*
|
2011-06-30 |
2018-01-16 |
Чугаи Сейяку Кабусики Кайся |
Heterodimerizated polypeptide
|
|
UA117901C2
(en)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
|
|
EP2543680A1
(en)
*
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
WO2013010840A2
(en)
|
2011-07-18 |
2013-01-24 |
Arts Biologics A/S |
Long acting biologically active luteinizing hormone (lh) compound
|
|
EP2736925A2
(en)
*
|
2011-07-27 |
2014-06-04 |
Glaxo Group Limited |
Anti-vegf single variable domains fused to fc domains
|
|
WO2013022782A1
(en)
|
2011-08-05 |
2013-02-14 |
Regeneron Pharmaceuticals, Inc. |
Humanized universal light chain mice
|
|
MX2014001766A
(en)
|
2011-08-17 |
2014-05-01 |
Genentech Inc |
Neuregulin antibodies and uses thereof.
|
|
CA2844540C
(en)
|
2011-08-23 |
2018-10-16 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
RS56879B1
(en)
|
2011-08-23 |
2018-04-30 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN103890006A
(en)
|
2011-08-23 |
2014-06-25 |
罗切格利卡特公司 |
Anti-mcsp antibodies
|
|
EP2748202B1
(en)
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
EP2748197A2
(en)
|
2011-08-26 |
2014-07-02 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
JP2014534949A
(en)
|
2011-09-19 |
2014-12-25 |
ジェネンテック， インコーポレイテッド |
Combination treatment comprising C-MET antagonist and B-RAF antagonist
|
|
MY173865A
(en)
|
2011-09-22 |
2020-02-25 |
Amgen Inc |
Cd27l antigen binding proteins
|
|
EP2758073B1
(en)
|
2011-09-23 |
2018-10-31 |
OncoMed Pharmaceuticals, Inc. |
Vegf/dll4 binding agents and uses thereof
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
WO2013052155A1
(en)
|
2011-10-05 |
2013-04-11 |
Genentech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
MX359384B
(en)
|
2011-10-11 |
2018-09-25 |
Genentech Inc |
Improved assembly of bispecific antibodies.
|
|
HUE039133T2
(en)
|
2011-10-14 |
2018-12-28 |
Hoffmann La Roche |
ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
|
|
EP2766000A2
(en)
|
2011-10-15 |
2014-08-20 |
F.Hoffmann-La Roche Ag |
Scd1 antagonists for treating cancer
|
|
CA2852468A1
(en)
|
2011-10-18 |
2013-04-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocyles
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
SG10201805291TA
(en)
|
2011-10-27 |
2018-08-30 |
Genmab As |
Production of heterodimeric proteins
|
|
AU2012328980A1
(en)
|
2011-10-28 |
2014-04-24 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
ES2732712T3
(en)
|
2011-10-31 |
2019-11-25 |
Chugai Pharmaceutical Co Ltd |
Antigen binding molecule that has a regulated conjugation between the heavy chain and the light chain
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
|
US20130142809A1
(en)
|
2011-11-23 |
2013-06-06 |
Andrew A. Welcher |
METHODS OF TREATMENT USING AN IFN gamma INHIBITOR
|
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
|
WO2013096221A1
(en)
|
2011-12-21 |
2013-06-27 |
Amgen Inc. |
Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
|
|
HRP20200744T1
(en)
|
2011-12-22 |
2020-07-24 |
F. Hoffmann - La Roche Ag |
ORGANIZATION OF EXPRESSION VECTOR, NEW PROCEDURES FOR GENERATION OF CELL PRODUCTION AND THEIR USE FOR RECOMBINANT POLYPEPTIDE PRODUCTION
|
|
EP2794662A1
(en)
|
2011-12-22 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
|
WO2013092743A2
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
UY34558A
(en)
|
2011-12-30 |
2013-07-31 |
Abbvie Inc |
DUAL SPECIFIC UNION PROTEINS DIRECTED AGAINST IL-13 AND / OR IL-17
|
|
CN102558355B
(en)
*
|
2011-12-31 |
2015-02-25 |
苏州康宁杰瑞生物科技有限公司 |
Heterodimer FC (fiber channel) modification method based on charge network and preparation method of heterodimer protein
|
|
EP2804629A1
(en)
|
2012-01-18 |
2014-11-26 |
Genentech, Inc. |
Anti-lrp5 antibodies and methods of use
|
|
US20130183294A1
(en)
|
2012-01-18 |
2013-07-18 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
|
BR112014018575A2
(en)
*
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
Growth Differentiation Factor 15 Polypeptides (gdf-15)
|
|
EP2809682B1
(en)
|
2012-02-03 |
2020-04-08 |
F.Hoffmann-La Roche Ag |
Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
|
|
SG10201704849PA
(en)
|
2012-02-09 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
RU2014133069A
(en)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
R-SPONDIN TRANSLOCATIONS AND WAYS WITH THEIR USE
|
|
CN104125852B9
(en)
|
2012-02-15 |
2017-05-17 |
弗·哈夫曼-拉罗切有限公司 |
Fc-receptor based affinity chromatography
|
|
SG10201606775YA
(en)
|
2012-02-15 |
2016-10-28 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles
|
|
HK1205454A1
(en)
|
2012-02-15 |
2015-12-18 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
|
JP2015514710A
(en)
|
2012-03-27 |
2015-05-21 |
ジェネンテック， インコーポレイテッド |
Diagnosis and treatment of HER3 inhibitors
|
|
US9550819B2
(en)
|
2012-03-27 |
2017-01-24 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
|
AR090549A1
(en)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
ANTI-LGR5 AND IMMUNOCATE PLAYERS
|
|
KR101674784B1
(en)
|
2012-04-05 |
2016-11-09 |
에프. 호프만-라 로슈 아게 |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
|
CN114163530B
(en)
*
|
2012-04-20 |
2025-04-29 |
美勒斯公司 |
Methods and means for producing immunoglobulin-like molecules
|
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
WO2013166594A1
(en)
*
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
WO2013166604A1
(en)
*
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Single-arm monovalent antibody constructs and uses thereof
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
UY34813A
(en)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER
|
|
EP3594239B1
(en)
|
2012-05-21 |
2024-10-30 |
F. Hoffmann-La Roche AG |
Methods for improving safety of blood-brain barrier transport
|
|
WO2013177470A1
(en)
|
2012-05-23 |
2013-11-28 |
Genentech, Inc. |
Selection method for therapeutic agents
|
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
|
WO2013188855A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
CN104619722B
(en)
|
2012-06-22 |
2022-10-04 |
达特茅斯大学理事会 |
Novel VISTA-IG constructs and use of VISTA-IG for treatment of autoimmune, allergic and inflammatory diseases
|
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
ES2604012T3
(en)
|
2012-07-04 |
2017-03-02 |
F. Hoffmann-La Roche Ag |
Covalently bound antigen-antibody conjugates
|
|
RU2630664C2
(en)
|
2012-07-04 |
2017-09-11 |
Ф. Хоффманн-Ля Рош Аг |
Theophylline antibodies and methods for their application
|
|
WO2014006123A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
|
CA3188124A1
(en)
|
2012-07-05 |
2014-01-09 |
Genentech, Inc. |
Expression and secretion system
|
|
BR112015000167B1
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
DIMERIC PROTEIN, PROTEIN, COMPOSITION, KIT OF PARTS AND THEIR USES, AS WELL AS A METHOD TO INCREASE THE OLIGOMERIZATION IN SOLUTION OF A DIMERIC PROTEIN COMPRISING A FIRST AND SECOND POLYPEPTIDE, EACH COMPRISING AT LEAST ONE CH2 AND CH3 REGIONS HUMAN AND VARIANT DIMER PROTEIN
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
US20140030282A1
(en)
|
2012-07-09 |
2014-01-30 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates
|
|
KR20150027829A
(en)
|
2012-07-09 |
2015-03-12 |
제넨테크, 인크. |
Immunoconjucates comprising anti-CD22 antibodies
|
|
SG11201500093TA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd79b antibodies
|
|
TW201408696A
(en)
|
2012-07-09 |
2014-03-01 |
Genentech Inc |
Anti-CD22 antibodies and immunoconjugates
|
|
WO2014011988A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
|
WO2014012085A2
(en)
*
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
|
|
SMT202100621T1
(en)
|
2012-07-13 |
2022-01-10 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
CA2878640C
(en)
|
2012-07-13 |
2023-10-24 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
MX366178B
(en)
|
2012-07-19 |
2019-07-01 |
Amgen Inc |
Human btnl3 proteins, nucleic acids, and antibodies and uses thereof.
|
|
CN102851338A
(en)
*
|
2012-07-25 |
2013-01-02 |
苏州康宁杰瑞生物科技有限公司 |
Method for preparing homodimer protein mixture by using charge repulsive interaction
|
|
PL3434695T3
(en)
|
2012-08-07 |
2021-05-17 |
Roche Glycart Ag |
Improved immunotherapy
|
|
MX2015001678A
(en)
|
2012-08-09 |
2015-08-14 |
Roche Glycart Ag |
Asgpr antibodies and uses thereof.
|
|
AU2013306700B2
(en)
|
2012-08-24 |
2019-05-02 |
Chugai Seiyaku Kabushiki Kaisha |
FcgammaRIIb-specific Fc region variant
|
|
JP6774164B2
(en)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
Mouse FcγRII specific Fc antibody
|
|
EP2892558B1
(en)
|
2012-09-07 |
2019-04-10 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
CA2886036A1
(en)
|
2012-09-25 |
2014-04-03 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
SG10201705787VA
(en)
|
2012-09-27 |
2017-08-30 |
Merus Nv |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
|
EP2904093B1
(en)
|
2012-10-03 |
2019-04-10 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
|
JP6273205B2
(en)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
Heterodimeric protein composition
|
|
EP2904016B1
(en)
|
2012-10-08 |
2018-11-14 |
Roche Glycart AG |
Fc-free antibodies comprising two fab-fragments and methods of use
|
|
EP2914961A4
(en)
|
2012-10-31 |
2016-04-20 |
Oncomed Pharm Inc |
METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
|
|
KR20190096459A
(en)
|
2012-11-01 |
2019-08-19 |
애브비 인코포레이티드 |
Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
|
|
CA2887285A1
(en)
|
2012-11-01 |
2014-05-08 |
Aileron Therapeutics, Inc. |
Disubstituted amino acids and methods of preparation and use thereof
|
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
|
ES2949394T3
(en)
|
2012-11-05 |
2023-09-28 |
Found Medicine Inc |
Novel fusion molecules and their uses
|
|
CN104797599A
(en)
|
2012-11-05 |
2015-07-22 |
全药工业株式会社 |
Method for preparing antibody or antibody composition
|
|
CN104755500B
(en)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
HER3 antigen binding proteins that bind to the HER3 beta-hairpin
|
|
MA38176A1
(en)
|
2012-11-13 |
2017-06-30 |
Genentech Inc |
Novel anti-haemagglutinin antibody, useful for the treatment, inhibition or prevention of viral influenza infection
|
|
WO2014079000A1
(en)
*
|
2012-11-21 |
2014-05-30 |
Wuhan Yzy Biopharma Co., Ltd. |
Bispecific antibody
|
|
UY35148A
(en)
*
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
HETERODIMERIC IMMUNOGLOBULINS
|
|
JP6385357B2
(en)
*
|
2012-11-27 |
2018-09-05 |
アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ |
Heterologous dimer of antibody heavy chain constant region, CH3 domain mutant pair that induces high-efficiency formation, production method and use thereof
|
|
MX385344B
(en)
|
2012-11-28 |
2025-03-18 |
Zymeworks Bc Inc |
GENETICALLY MODIFIED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND THEIR USES.
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
KR102249779B1
(en)
|
2012-12-27 |
2021-05-07 |
추가이 세이야쿠 가부시키가이샤 |
Heterodimerized polypeptide
|
|
EA201500741A1
(en)
|
2013-01-10 |
2016-01-29 |
Генмаб Б.В. |
HUMAN FG IGG1 OPTIONS AND THEIR APPLICATION
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10738132B2
(en)
|
2013-01-14 |
2020-08-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
|
CA2899170C
(en)
|
2013-01-30 |
2022-08-02 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods of use in treating metabolic disorders
|
|
HK1218930A1
(en)
*
|
2013-02-08 |
2017-03-17 |
Abbvie Stemcentrx Llc |
Novel multispecific constructs
|
|
EP3744728A1
(en)
|
2013-02-12 |
2020-12-02 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
ES2870802T3
(en)
|
2013-02-12 |
2021-10-27 |
Bristol Myers Squibb Co |
High pH Protein Refolding Methods
|
|
HUE067221T2
(en)
*
|
2013-02-15 |
2024-10-28 |
R Pharm Int Llc |
Il-1beta inhibitor composition and use thereof
|
|
JP2016509045A
(en)
|
2013-02-22 |
2016-03-24 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
How to treat cancer and prevent drug resistance
|
|
EP2961772A1
(en)
|
2013-02-26 |
2016-01-06 |
Roche Glycart AG |
Anti-mcsp antibodies
|
|
MX2015010350A
(en)
|
2013-02-26 |
2015-10-29 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules.
|
|
EP2961771B1
(en)
|
2013-02-26 |
2020-01-01 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules specific to cd3 and cea
|
|
HK1211299A1
(en)
|
2013-02-26 |
2016-05-20 |
罗切格利卡特公司 |
Bispecific t cell activating antigen binding molecules
|
|
JP2016510755A
(en)
|
2013-03-06 |
2016-04-11 |
メリマック ファーマシューティカルズ インコーポレーティッド |
Anti-C-MET Tandem Fc Bispecific Antibody
|
|
WO2014138364A2
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
EP2975061A4
(en)
*
|
2013-03-13 |
2017-03-01 |
Ibentrus Inc. |
Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
WO2014153030A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
EP3299391B1
(en)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
CA2903480A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
|
AU2014235453A1
(en)
|
2013-03-15 |
2015-10-08 |
Genentech, Inc. |
Biomarkers and methods of treating PD-1 and PD-L1 related conditions
|
|
CN111138543B
(en)
*
|
2013-03-15 |
2024-06-11 |
Xencor股份有限公司 |
Heterodimer protein
|
|
AU2014236815B2
(en)
|
2013-03-15 |
2019-04-04 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
KR20150128849A
(en)
|
2013-03-15 |
2015-11-18 |
얀센 바이오테크 인코포레이티드 |
Interferon alpha and omega antibody antagonists
|
|
JP2016517441A
(en)
|
2013-03-15 |
2016-06-16 |
ジェネンテック， インコーポレイテッド |
Anti-CRTh2 antibody and method of use
|
|
WO2014150877A2
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
MX2015011899A
(en)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Methods of treating cancer and preventing cancer drug resistance.
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
MX357011B
(en)
|
2013-03-15 |
2018-06-22 |
Amgen Inc |
Heterodimeric bispecific antibodies.
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
BR112015023797A2
(en)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
dual specificity binding proteins directed against il-1b and / or il-17
|
|
EP2976361B1
(en)
|
2013-03-18 |
2018-07-18 |
BiocerOX Products B.V. |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
WO2014163101A1
(en)
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Fc region variant
|
|
UA118028C2
(en)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
|
|
CN118561989A
(en)
|
2013-04-29 |
2024-08-30 |
豪夫迈·罗氏有限公司 |
FC-receptor binding modified asymmetric antibodies and methods of use
|
|
TWI653243B
(en)
|
2013-04-29 |
2019-03-11 |
赫孚孟拉羅股份公司 |
Anti-IGF-1R antibody against FcRn binding and use thereof for treating vascular eye diseases
|
|
HK1213578A1
(en)
|
2013-04-29 |
2016-07-08 |
豪夫迈‧罗氏有限公司 |
Human fcrn-binding modified antibodies and methods of use
|
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
PL3594240T3
(en)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
KR101882366B1
(en)
|
2013-05-30 |
2018-07-30 |
키닉사 파마슈티컬스, 리미티드 |
Oncostatin m receptor antigen binding proteins
|
|
DK3016681T5
(en)
|
2013-07-05 |
2020-05-04 |
Genmab As |
Humanized or chimeric CD3 antibodies
|
|
MX369152B
(en)
|
2013-07-31 |
2019-10-30 |
Amgen Inc |
Growth differentiation factor 15 (gdf-15) constructs.
|
|
AU2014332458B2
(en)
*
|
2013-09-05 |
2020-03-12 |
Igm Biosciences, Inc. |
Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
|
|
JP2016537399A
(en)
|
2013-09-17 |
2016-12-01 |
ジェネンテック， インコーポレイテッド |
Method using anti-LGR5 antibody
|
|
EP3049440B1
(en)
|
2013-09-25 |
2020-03-25 |
Amgen Inc. |
V-c-fc-v-c antibody
|
|
SG10201803449VA
(en)
*
|
2013-09-27 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
|
KR20160044060A
(en)
|
2013-10-11 |
2016-04-22 |
에프. 호프만-라 로슈 아게 |
Multispecific domain exchanged common variable light chain antibodies
|
|
EP3055328A1
(en)
|
2013-10-11 |
2016-08-17 |
F. Hoffmann-La Roche AG |
Nsp4 inhibitors and methods of use
|
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
|
SG11201603127WA
(en)
|
2013-10-23 |
2016-05-30 |
Genentech Inc |
Methods of diagnosing and treating eosinophilic disorders
|
|
SI3065774T1
(en)
|
2013-11-06 |
2021-11-30 |
Janssen Biotech, Inc. |
Anti-ccl17 antibodies
|
|
US10273303B2
(en)
|
2013-11-13 |
2019-04-30 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
|
SI3071597T1
(en)
|
2013-11-21 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
|
WO2015077891A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
|
HRP20200384T1
(en)
|
2013-12-20 |
2020-06-12 |
F. Hoffmann - La Roche Ag |
HUMANIZED ANTI-TAU (PS422) ANTIBODIES AND METHODS OF USE
|
|
TWI670283B
(en)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
Antibodies and methods of use
|
|
SI3712174T1
(en)
|
2013-12-24 |
2022-06-30 |
Janssen Pharmaceutica Nv |
VISTA antibodies and particles
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
US10561737B2
(en)
|
2014-01-03 |
2020-02-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
KR102278979B1
(en)
|
2014-01-03 |
2021-07-19 |
에프. 호프만-라 로슈 아게 |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
|
JP6521464B2
(en)
|
2014-01-03 |
2019-05-29 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Covalently linked polypeptide toxin-antibody conjugates
|
|
RU2694659C2
(en)
|
2014-01-06 |
2019-07-16 |
Ф. Хоффманн-Ля Рош Аг |
Monovalent carrier modules across blood-brain barrier
|
|
AU2014377106B2
(en)
|
2014-01-08 |
2019-10-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-15 heterodimeric protein and uses thereof
|
|
CN105916880B
(en)
|
2014-01-15 |
2020-01-17 |
豪夫迈·罗氏有限公司 |
Fc region variants with improved protein A binding
|
|
CA2931986A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
KR20160111469A
(en)
|
2014-01-24 |
2016-09-26 |
제넨테크, 인크. |
Methods of using anti-STEAP1 antibodies and immunoconjugates
|
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
TIM-3 Antibody Molecules and Their Uses
|
|
BR112016018170A2
(en)
|
2014-02-08 |
2018-02-20 |
Genentech, Inc. |
Methods To Treat Alzheimer's Disease
|
|
CN106456729A
(en)
|
2014-02-08 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
Ways to treat Alzheimer's disease
|
|
EA201691610A8
(en)
|
2014-02-12 |
2018-05-31 |
Дженентек, Инк. |
ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
|
|
CR20160379A
(en)
|
2014-02-21 |
2016-10-07 |
Genentech Inc |
BISPECIFIC ANTIBODIES ANTI-IL 13 / IL-17 AND ITS USES
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
ES2816624T3
(en)
|
2014-02-28 |
2021-04-05 |
Merus Nv |
Antibodies that bind EGFR and ERBB3
|
|
SG11201607104RA
(en)
|
2014-02-28 |
2016-09-29 |
Merus Nv |
Antibody that binds erbb-2 and erbb-3
|
|
LT3116909T
(en)
|
2014-03-14 |
2020-02-10 |
Novartis Ag |
ANTI-BODY MOLECULES AGAINST LAG-3 AND THEIR USE
|
|
AU2015229035B2
(en)
|
2014-03-14 |
2021-08-05 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
CN106163547A
(en)
|
2014-03-15 |
2016-11-23 |
诺华股份有限公司 |
Use Chimeric antigen receptor treatment cancer
|
|
KR102846903B1
(en)
|
2014-03-21 |
2025-08-20 |
리제너론 파마슈티칼스 인코포레이티드 |
Non-human animals that make single domain binding proteins
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
WO2015148531A1
(en)
|
2014-03-24 |
2015-10-01 |
Genentech, Inc. |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
US12180264B2
(en)
|
2014-03-24 |
2024-12-31 |
R-Pharm Overseas, Inc. |
IL1-R1 derived inhibitor of IL-1β and use thereof
|
|
LT3122781T
(en)
|
2014-03-28 |
2020-03-25 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
EP3126394B1
(en)
|
2014-03-31 |
2019-10-30 |
F.Hoffmann-La Roche Ag |
Anti-ox40 antibodies and methods of use
|
|
KR20160146747A
(en)
|
2014-03-31 |
2016-12-21 |
제넨테크, 인크. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
US20170022291A1
(en)
|
2014-04-01 |
2017-01-26 |
Adimab, Llc |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
UA117289C2
(en)
*
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
MULTISPECIFIC ANTIBODY
|
|
CN106164288A
(en)
|
2014-04-02 |
2016-11-23 |
豪夫迈·罗氏有限公司 |
Method for detecting mismatches in light chains of multispecific antibodies
|
|
MY194892A
(en)
|
2014-04-07 |
2022-12-22 |
Chugai Pharmaceutical Co Ltd |
Immunoactivating antigen-binding molecule
|
|
WO2015160940A1
(en)
*
|
2014-04-15 |
2015-10-22 |
President And Fellows Of Harvard College |
Bi-specific agents
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
ES2962694T3
(en)
|
2014-05-02 |
2024-03-20 |
Momenta Pharmaceuticals Inc |
Compositions and procedures related to manipulated Fc constructs
|
|
HRP20231139T1
(en)
|
2014-05-06 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Production of heteromultimeric proteins using mammalian cells
|
|
CN106459954A
(en)
|
2014-05-13 |
2017-02-22 |
中外制药株式会社 |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
WO2015175375A1
(en)
|
2014-05-13 |
2015-11-19 |
Short Jay M |
Conditionally active biological proteins
|
|
EP3143043B1
(en)
*
|
2014-05-16 |
2022-12-14 |
Pfizer Inc. |
Bispecific antibodies with engineered ch1-cl interfaces
|
|
WO2015179658A2
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
|
CN106661622B
(en)
|
2014-05-23 |
2020-08-21 |
豪夫迈·罗氏有限公司 |
MIT biomarkers and how to use them
|
|
HK1231490A1
(en)
|
2014-05-28 |
2017-12-22 |
Zymeworks, Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
|
WO2015187977A1
(en)
|
2014-06-04 |
2015-12-10 |
Acceleron Pharma, Inc. |
Methods and compositions for treatment of disorders with follistatin polypeptides
|
|
US10010498B2
(en)
|
2014-06-04 |
2018-07-03 |
Acceleron Pharma Inc. |
Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
|
|
JP6997619B2
(en)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
Use of VISTA agonists and VISTA antagonists for suppression or enhancement of humoral immunity
|
|
CA2949982A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
TWI713453B
(en)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
Interferon alpha and omega antibody antagonists
|
|
AR100978A1
(en)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
|
|
MX384037B
(en)
|
2014-06-26 |
2025-03-14 |
Hoffmann La Roche |
ANTI-BROMODEOXYURIDINE (BRDU) ANTIBODIES AND METHODS OF USE.
|
|
AU2015279321B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma, S.A. |
Multispecific antigen binding proteins
|
|
AU2015279316B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma |
Multispecific NKp46 binding proteins
|
|
TW201623329A
(en)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof
|
|
HRP20192243T1
(en)
|
2014-07-03 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Polypeptide expression systems
|
|
WO2016005545A1
(en)
|
2014-07-10 |
2016-01-14 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington's disease
|
|
RU2715038C2
(en)
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Anti-pd-l1 antibodies and methods for their diagnostic use
|
|
PT3169706T
(en)
|
2014-07-11 |
2020-03-13 |
Genmab As |
ANTIBODIES THAT CONNECT TO AXL
|
|
RU2017103289A
(en)
|
2014-07-11 |
2018-08-14 |
Дженентек, Инк. |
INHIBITING THE NOTCH WAY
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
BR112017001242A2
(en)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
cancer treatment using a cd33 chimeric antigen receptor
|
|
US9777073B2
(en)
*
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
|
EP3172237A2
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP6744292B2
(en)
*
|
2014-07-29 |
2020-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Multispecific antibody
|
|
SG11201700378PA
(en)
|
2014-07-30 |
2017-02-27 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
PE20170263A1
(en)
|
2014-08-04 |
2017-03-30 |
Hoffmann La Roche |
T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
|
TW202140557A
(en)
|
2014-08-19 |
2021-11-01 |
瑞士商諾華公司 |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
MX2017002605A
(en)
|
2014-08-28 |
2017-05-19 |
Bioatla Llc |
Conditionally active chimeric antigen receptors for modified t-cells.
|
|
CA2959786A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
MA40608A
(en)
|
2014-09-09 |
2016-03-17 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
CN113698485A
(en)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
anti-B7-H4 antibodies and immunoconjugates
|
|
MX2017003123A
(en)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Cysteine engineered antibodies and conjugates.
|
|
PE20170935A1
(en)
|
2014-09-12 |
2017-07-13 |
Genentech Inc |
ANTI-HER2 AND IMMUNOCONJUGATED ANTIBODIES
|
|
BR112017004802A2
(en)
|
2014-09-12 |
2017-12-12 |
Genentech Inc |
anti-cll-1 and immunoconjugate antibodies
|
|
TW201620938A
(en)
|
2014-09-15 |
2016-06-16 |
安美基公司 |
Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
|
|
MX2017003645A
(en)
|
2014-09-17 |
2017-05-30 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy.
|
|
BR112017004953A2
(en)
|
2014-09-17 |
2017-12-05 |
Genentech Inc |
immunoconjugate, pharmaceutical formulation, method of treatment and method of inhibiting cell proliferation
|
|
AU2015320678B2
(en)
|
2014-09-23 |
2021-07-22 |
Genentech, Inc. |
Method of using anti-CD79b immunoconjugates
|
|
JP2017533889A
(en)
|
2014-09-24 |
2017-11-16 |
エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Peptidomimetic macrocycles and uses thereof
|
|
SG10201902598VA
(en)
|
2014-09-24 |
2019-04-29 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and formulations thereof
|
|
WO2016046778A2
(en)
|
2014-09-25 |
2016-03-31 |
Amgen Inc |
Protease-activatable bispecific proteins
|
|
MA40764A
(en)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT INDUCING CYTOTOXICITY
|
|
CA2963692A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
|
JP6877339B2
(en)
|
2014-10-14 |
2021-05-26 |
ノバルティス アーゲー |
Antibody molecule against PD-L1 and its use
|
|
WO2016061389A2
(en)
|
2014-10-16 |
2016-04-21 |
Genentech, Inc. |
Anti-alpha-synuclein antibodies and methods of use
|
|
CN107530419B
(en)
|
2014-10-31 |
2021-05-18 |
昂考梅德药品有限公司 |
Combination therapy to treat disease
|
|
DK3212226T3
(en)
|
2014-10-31 |
2020-06-15 |
Ngm Biopharmaceuticals Inc |
COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS
|
|
US20170258835A1
(en)
|
2014-10-31 |
2017-09-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for modified t cells
|
|
MX2017005750A
(en)
|
2014-11-03 |
2017-12-15 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof.
|
|
EP3215637B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Methods and biomarkers for predicting efficacy and valuation of an ox40 agonist treatment
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
AR102522A1
(en)
|
2014-11-06 |
2017-03-08 |
Hoffmann La Roche |
FC REGION VARIATIONS WITH MODIFIED PROPERTIES OF UNION TO FCRN AND PROTEIN A
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
RU2714116C2
(en)
|
2014-11-06 |
2020-02-11 |
Ф. Хоффманн-Ля Рош Аг |
VARIANTS OF Fc-DOMAIN WITH MODIFIED FcRn BINDING AND METHODS OF APPLICATION THEREOF
|
|
WO2016077369A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Animal model for nephropathy and agents for treating the same
|
|
BR112017009728A2
(en)
|
2014-11-10 |
2018-02-06 |
Genentech, Inc. |
isolated antibodies, isolated nucleic acid, vector, host cell, method for producing antibody, composition, uses of an antibody and methods of treating a disorder
|
|
DK3489256T3
(en)
|
2014-11-14 |
2021-05-25 |
Hoffmann La Roche |
Antigen-binding molecules comprising a TNF family ligand trimer
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
US10882920B2
(en)
|
2014-11-19 |
2021-01-05 |
Genentech, Inc. |
Antibodies against BACE1 and use thereof for neural disease immunotherapy
|
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
|
LT3789402T
(en)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
CA2968162A1
(en)
|
2014-11-20 |
2016-05-26 |
F. Hoffmann-La Roche Ag |
Common light chains and methods of use
|
|
DK3221356T3
(en)
|
2014-11-20 |
2020-11-02 |
Hoffmann La Roche |
T cell activating bispecific antigen binding molecules against folr1 and cd3
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
TN2017000223A1
(en)
|
2014-11-26 |
2018-10-19 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
IL252467B
(en)
|
2014-11-26 |
2022-06-01 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and cd38
|
|
WO2016082044A1
(en)
|
2014-11-27 |
2016-06-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
JP6721590B2
(en)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Multispecific antibody
|
|
CA2969717A1
(en)
|
2014-12-04 |
2016-06-09 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of acute myeloid leukemia
|
|
PT3227336T
(en)
|
2014-12-05 |
2019-09-09 |
Hoffmann La Roche |
Anti-cd79b antibodies and methods of use
|
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
|
CN107207591A
(en)
|
2014-12-10 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
Blood-brain barrier receptor antibody and application method
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
CN107002114A
(en)
|
2014-12-18 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
Assays and methods for determining CDC eliciting antibodies
|
|
WO2016097300A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
JP6227191B1
(en)
|
2014-12-19 |
2017-11-08 |
中外製薬株式会社 |
Anti-myostatin antibody, polypeptide comprising mutant Fc region, and method of use
|
|
US9765135B2
(en)
|
2014-12-19 |
2017-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-C5 antibodies
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
CN110658340B
(en)
*
|
2015-01-08 |
2023-10-31 |
苏州康宁杰瑞生物科技有限公司 |
Bispecific antibodies or antibody mixtures with a common light chain
|
|
KR102663073B1
(en)
|
2015-01-08 |
2024-05-07 |
젠맵 에이/에스 |
Bispecific antibodies against CD3 and CD20
|
|
MA41375A
(en)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
BISPECIFIC IGG ANTIBODIES AND THEIR PREPARATION PROCESSES
|
|
EP3247723A1
(en)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
|
CA3248123A1
(en)
|
2015-01-31 |
2025-11-29 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for t cell delivery of therapeutic molecules
|
|
CN114773470A
(en)
|
2015-02-05 |
2022-07-22 |
中外制药株式会社 |
Antibodies comprising an ion concentration-dependent antigen-binding domain, FC region variants, IL-8-binding antibodies and uses thereof
|
|
SG11201705988UA
(en)
|
2015-02-24 |
2017-08-30 |
Bioatla Llc |
Conditionally active biological proteins
|
|
WO2016141110A1
(en)
|
2015-03-03 |
2016-09-09 |
Schlumberger Technology Corporation |
Multi-mode acoustic tool and method
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
SG11201707186YA
(en)
|
2015-03-06 |
2017-10-30 |
Genentech Inc |
Ultrapurified dsba and dsbc and methods of making and using the same
|
|
MX2017011486A
(en)
|
2015-03-16 |
2018-06-15 |
Genentech Inc |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases.
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
JP2018516844A
(en)
|
2015-03-20 |
2018-06-28 |
エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Peptidomimetic macrocycles and uses thereof
|
|
JP2018510637A
(en)
*
|
2015-03-26 |
2018-04-19 |
アクセルロン ファーマ， インコーポレイテッド |
Follistatin-related fusion protein and use thereof
|
|
JP7082484B2
(en)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
Method for Producing Polypeptide Heterogeneous Multimer
|
|
WO2016161390A1
(en)
|
2015-04-03 |
2016-10-06 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
|
CN114736307A
(en)
|
2015-04-06 |
2022-07-12 |
阿塞勒隆制药公司 |
TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
|
|
MA41919A
(en)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
|
|
JP6810702B2
(en)
|
2015-04-06 |
2021-01-06 |
アクセルロン ファーマ インコーポレイテッド |
Single-arm type I and type II receptor fusion proteins and uses thereof
|
|
EP3280736A1
(en)
|
2015-04-07 |
2018-02-14 |
F. Hoffmann-La Roche AG |
Antigen binding complex having agonistic activity and methods of use
|
|
CA2981851A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cells
|
|
IL283764B2
(en)
|
2015-04-10 |
2024-01-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
CN108472360B
(en)
|
2015-04-10 |
2023-01-17 |
阿迪马布有限责任公司 |
Method for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
|
WO2016166348A1
(en)
|
2015-04-17 |
2016-10-20 |
Elsalys Biotech |
Anti-tyro3 antibodies and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
SI3286315T1
(en)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Methods of identifying bacteria comprising binding polypeptides
|
|
JP6952605B2
(en)
|
2015-04-24 |
2021-10-20 |
ジェネンテック， インコーポレイテッド |
Multispecific antigen binding protein
|
|
EP3294771A1
(en)
|
2015-05-11 |
2018-03-21 |
H. Hoffnabb-La Roche Ag |
Compositions and methods of treating lupus nephritis
|
|
HRP20201900T4
(en)
|
2015-05-12 |
2024-06-07 |
F. Hoffmann - La Roche Ag |
THERAPEUTIC AND DIAGNOSTIC PROCEDURES IN CANCER
|
|
WO2016187546A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Biotech, Inc. |
Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
|
|
WO2016191750A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
|
HK1250723A1
(en)
|
2015-05-29 |
2019-01-11 |
F. Hoffmann-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
TWI827405B
(en)
|
2015-06-05 |
2023-12-21 |
美商建南德克公司 |
Anti-tau antibodies and methods of use
|
|
CA2985483A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
TW201710286A
(en)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
Binding proteins against VEGF, PDGF, and/or their receptors
|
|
JP2018524295A
(en)
|
2015-06-15 |
2018-08-30 |
ジェネンテック， インコーポレイテッド |
Antibodies and immune complexes
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
HUE063270T2
(en)
|
2015-06-16 |
2024-01-28 |
Hoffmann La Roche |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
|
AU2016280159A1
(en)
|
2015-06-17 |
2017-12-07 |
Genentech, Inc. |
Anti-HER2 antibodies and methods of use
|
|
US10668149B2
(en)
|
2015-06-22 |
2020-06-02 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
|
EP3313881A1
(en)
|
2015-06-23 |
2018-05-02 |
Innate Pharma |
Multispecific nk engager proteins
|
|
CN107921120A
(en)
|
2015-06-24 |
2018-04-17 |
詹森生物科技公司 |
Solid tumor is adjusted and treated with the antibody mediated immunity of specific binding CD38
|
|
CN113929779B
(en)
|
2015-06-24 |
2025-02-25 |
豪夫迈·罗氏有限公司 |
Humanized anti-Tau (pS422) antibodies and methods of use
|
|
WO2016207717A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
WO2016207091A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use
|
|
EP3314255B1
(en)
|
2015-06-25 |
2019-07-31 |
H. Hoffnabb-La Roche Ag |
Cell based assay for determining antibody or ligand binding and function
|
|
ES2878316T3
(en)
|
2015-06-29 |
2021-11-18 |
Ventana Med Syst Inc |
Materials and Procedures for Histochemical Assays for Human Pro-epiregulin and Ampheregulin
|
|
US20170029520A1
(en)
|
2015-06-29 |
2017-02-02 |
Genentech, Inc. |
Compositions and methods for use in organ transplantation
|
|
US10059741B2
(en)
|
2015-07-01 |
2018-08-28 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
WO2017005649A1
(en)
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
EP3319993B1
(en)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
EA201890028A1
(en)
|
2015-07-10 |
2018-08-31 |
Мерус Н.В. |
HUMAN CD3 ANTIBODY
|
|
CN114989302B
(en)
|
2015-07-15 |
2025-08-05 |
根马布股份公司 |
Humanized or chimeric CD3 antibodies
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
WO2017019896A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3964528A1
(en)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
SG10201906059VA
(en)
|
2015-07-30 |
2019-08-27 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
|
MX2018001522A
(en)
|
2015-08-05 |
2018-03-15 |
Janssen Biotech Inc |
Anti-cd154 antibodies and methods of using them.
|
|
EA034582B1
(en)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Sirp-alpha variant constructs and use thereof
|
|
GEP20217326B
(en)
|
2015-08-07 |
2021-11-25 |
Alx Oncology Inc |
Constructs having a sirp-alpha domain or variant thereof
|
|
CN105384825B
(en)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
|
|
ES2995985T3
(en)
|
2015-08-13 |
2025-02-11 |
Amgen Inc |
Charged depth filtration of antigen-binding proteins
|
|
BR112017026543A2
(en)
|
2015-08-26 |
2018-08-14 |
Bison Therapeutics Inc |
multispecific antibody platform and related methods
|
|
WO2017040324A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
WO2017040195A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
EP3347051A4
(en)
|
2015-09-10 |
2019-04-24 |
Affigen, Inc. |
Sequencing-directed selection of tumor theranostics
|
|
EP3347372A4
(en)
|
2015-09-10 |
2019-09-04 |
Aileron Therapeutics, Inc. |
PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
|
|
JP6932700B2
(en)
|
2015-09-15 |
2021-09-08 |
アムジエン・インコーポレーテツド |
Tetravalent bispecific antigen-binding proteins and tetravalent quadrispecific antigen-binding proteins, and their use
|
|
CN108271372B
(en)
|
2015-09-18 |
2021-07-09 |
中外制药株式会社 |
IL-8-binding antibody and its application
|
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
JP6967003B2
(en)
|
2015-09-23 |
2021-11-17 |
メレオ バイオファーマ ５ インコーポレイテッド |
Methods and compositions for the treatment of cancer
|
|
CA2992602A1
(en)
|
2015-09-23 |
2017-03-30 |
Genentech, Inc. |
Optimized variants of anti-vegf antibodies
|
|
US11142565B2
(en)
|
2015-09-24 |
2021-10-12 |
Abvitro Llc |
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
|
|
NZ739750A
(en)
|
2015-09-25 |
2019-11-29 |
Genentech Inc |
Anti-tigit antibodies and methods of use
|
|
JP7628764B2
(en)
|
2015-09-29 |
2025-02-12 |
アムジエン・インコーポレーテツド |
mod folkpon edge cargogo search carrier Signalsure procedure always Subaturch curl carrieresert match experiencesch suffer with Japan missed crgoc car
|
|
AR106188A1
(en)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
|
|
WO2017055539A1
(en)
*
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
MY192202A
(en)
|
2015-10-02 |
2022-08-06 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
|
EP3356403A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
MA43345A
(en)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
KR102072317B1
(en)
|
2015-10-02 |
2020-01-31 |
에프. 호프만-라 로슈 아게 |
Anti-PD1 Antibodies and Methods of Use
|
|
CN107849137B
(en)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
Bispecific anti-CEAXCD 3T cell activating antigen binding molecules
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
WO2017055399A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
|
JP2018533930A
(en)
|
2015-10-02 |
2018-11-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Bispecific T cell activation antigen binding molecule
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
WO2017055391A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
MY193013A
(en)
|
2015-10-07 |
2022-09-22 |
Hoffmann La Roche |
Bispecific antibodies with tetravalency for a costimulatory tnf receptor
|
|
EP4524161A3
(en)
|
2015-10-08 |
2025-06-04 |
Zymeworks BC Inc. |
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
|
KR101851380B1
(en)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
Method to generate CH3 domain mutant pairs of heterodimeric Fc using yeast mating and CH3 domain mutant pairs thereby
|
|
MA43354A
(en)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
|
|
MA45326A
(en)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
|
|
HRP20210483T1
(en)
|
2015-10-23 |
2021-07-09 |
Merus N.V. |
Binding molecules that inhibit cancer growth
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
EP3368568B1
(en)
|
2015-10-29 |
2022-04-06 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
|
EP3368578B1
(en)
|
2015-10-30 |
2021-03-17 |
H. Hoffnabb-La Roche Ag |
Anti-htra1 antibodies and methods of use thereof
|
|
SMT202100192T1
(en)
|
2015-11-03 |
2021-05-07 |
Janssen Biotech Inc |
Subcutaneous formulations of anti-cd38 antibodies and their uses
|
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
|
WO2017086367A1
(en)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
|
SG11201803956UA
(en)
|
2015-12-01 |
2018-06-28 |
Genmab Bv |
Anti-dr5 antibodies and methods of use thereof
|
|
KR20180085800A
(en)
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
CD3 and heterodimeric antibodies that bind to PSMA
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
CR20180318A
(en)
|
2015-12-14 |
2018-09-19 |
Macrogenics Inc |
BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME
|
|
CN106883297B
(en)
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
CH3 domain-based heterodimeric molecules, methods for their preparation and uses
|
|
CR20180365A
(en)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEINS OF UNION TO THE ANTI-TL1A / ANTI-TNF-a BISPECTIVE ANTIGEN AND ITS USES
|
|
EP4424322A3
(en)
|
2015-12-17 |
2025-04-16 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
EP3389713A2
(en)
|
2015-12-17 |
2018-10-24 |
Novartis AG |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
JP2019502698A
(en)
|
2015-12-17 |
2019-01-31 |
ヤンセン バイオテツク，インコーポレーテツド |
Antibodies that bind specifically to HLA-DR and uses thereof
|
|
SG10201707267RA
(en)
|
2015-12-18 |
2017-10-30 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
SI3390442T1
(en)
|
2015-12-18 |
2024-01-31 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
|
EP3397646A1
(en)
*
|
2015-12-28 |
2018-11-07 |
Massachusetts Institute of Technology |
Bispecific antibodies having constant region mutations and uses therefor
|
|
WO2017115773A1
(en)
|
2015-12-28 |
2017-07-06 |
中外製薬株式会社 |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
EP3400246B1
(en)
|
2016-01-08 |
2020-10-21 |
H. Hoffnabb-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
BR112018014762A2
(en)
|
2016-01-20 |
2018-12-26 |
Genentech Inc |
method of treating (early) alzheimer's disease
|
|
ES2847155T3
(en)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Multispecific molecules targeting CLL-1
|
|
CN109069626A
(en)
|
2016-02-12 |
2018-12-21 |
詹森药业有限公司 |
Anti-VISTA(B7H5) antibody
|
|
KR20180119632A
(en)
|
2016-02-29 |
2018-11-02 |
제넨테크, 인크. |
Treatment and Diagnosis Methods for Cancer
|
|
US12391759B2
(en)
|
2016-03-02 |
2025-08-19 |
Momenta Pharmaceuticals, Inc. |
Methods related to engineered Fc constructs
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
RU2746754C2
(en)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Cell damage inducing therapeutic medicinal product for anticancer therapy
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017162587A1
(en)
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
PL3433280T3
(en)
|
2016-03-22 |
2023-07-31 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
CN121431692A
(en)
|
2016-03-25 |
2026-01-30 |
豪夫迈·罗氏有限公司 |
Multiplex total antibodies and antibody conjugated drug quantification assays
|
|
SG11201807279QA
(en)
|
2016-03-31 |
2018-09-27 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
|
WO2017177013A1
(en)
|
2016-04-06 |
2017-10-12 |
Acceleron Pharma Inc. |
Alk7 antagonists and uses thereof
|
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
|
EP3442579A4
(en)
|
2016-04-15 |
2019-12-18 |
Immunext Inc. |
ANTI-HUMAN ANTI-VISTA ANTIBODIES AND USES THEREOF
|
|
CN109154613A
(en)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
For monitoring and the method for the treatment of cancer
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
MX395074B
(en)
|
2016-04-15 |
2025-03-24 |
Bioatla Llc |
Anti-AXL antibodies, antibody fragments and their immunoconjugates and their uses
|
|
CA3021027A1
(en)
|
2016-04-15 |
2017-10-19 |
Novartis Ag |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
CA3015371A1
(en)
|
2016-04-20 |
2017-10-26 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
|
SG10202010155YA
(en)
|
2016-04-20 |
2020-11-27 |
Regeneron Pharma |
Compositions and methods for making antibodies based on use of expression-enhancing loci
|
|
UA126900C2
(en)
|
2016-04-28 |
2023-02-22 |
Чугаі Сейяку Кабусікі Кайся |
ANTIBODY CONTAINING DRUG
|
|
AU2017259869A1
(en)
|
2016-05-02 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
The contorsbody - a single chain target binder
|
|
CN109071623B
(en)
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
Interleukin-2 muteins for expansion of T regulatory cells
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
CN109071652B
(en)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
Antigen binding molecules comprising TNF family ligand trimers and tenascin binding modules
|
|
JP7089483B2
(en)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Modified anti-tenascin antibody and usage
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
PL3455261T3
(en)
|
2016-05-13 |
2022-12-12 |
Bioatla, Inc. |
ANTI-ROR2 ANTIBODY, ANTIBODY FRAGMENTS, THEIR IMMUNOCJUGATES AND THEIR APPLICATIONS
|
|
EP3458608B1
(en)
|
2016-05-17 |
2025-07-23 |
F. Hoffmann-La Roche AG |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
JP2019522633A
(en)
|
2016-05-20 |
2019-08-15 |
ジェネンテック， インコーポレイテッド |
PROTAC antibody conjugates and methods of use
|
|
EP3484514B1
(en)
*
|
2016-05-23 |
2023-12-06 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc constructs
|
|
CN109475627B
(en)
*
|
2016-05-26 |
2023-01-06 |
齐鲁普吉湾生物治疗公司 |
Antibody mixtures
|
|
JP7022080B2
(en)
|
2016-05-27 |
2022-02-17 |
ジェネンテック， インコーポレイテッド |
Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
|
MA45255A
(en)
|
2016-06-14 |
2019-04-17 |
Xencor Inc |
BISPECIFIC CONTROL POINT INHIBITORS ANTIBODIES
|
|
MX2018014375A
(en)
|
2016-06-17 |
2019-04-22 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies and methods of use.
|
|
HRP20241323T1
(en)
|
2016-06-17 |
2024-12-20 |
F. Hoffmann - La Roche Ag |
PURIFICATION OF MULTISPECIFIC ANTIBODIES
|
|
CN109563160B
(en)
|
2016-06-24 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
Anti-polyubiquitin multispecific antibody
|
|
CA3029328A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
JP2019527678A
(en)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
Treatment of IgE-mediated diseases with antibodies that specifically bind to CD38
|
|
HRP20240603T1
(en)
|
2016-07-01 |
2024-07-19 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
EP3484922A1
(en)
|
2016-07-14 |
2019-05-22 |
Genmab A/S |
Multispecific antibodies against cd40 and cd137
|
|
LT3496739T
(en)
|
2016-07-15 |
2021-05-25 |
Acceleron Pharma Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LUNG HYPERTENSION
|
|
CN110461315B
(en)
|
2016-07-15 |
2025-05-02 |
诺华股份有限公司 |
Treatment and prevention of cytokine release syndrome using chimeric antigen receptors in combination with kinase inhibitors
|
|
US20230075499A1
(en)
*
|
2016-07-19 |
2023-03-09 |
Ibentrus, Inc. |
Bispecific proteins and methods for preparing same
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
CA3218290A1
(en)
|
2016-07-22 |
2018-01-25 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
|
SI3490582T1
(en)
|
2016-07-27 |
2024-09-30 |
Acceleron Pharma Inc. |
Compositions for use in treating myelofibrosis
|
|
TW201806619A
(en)
|
2016-07-28 |
2018-03-01 |
瑞士商諾華公司 |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
JP7050677B2
(en)
|
2016-07-29 |
2022-04-08 |
中外製薬株式会社 |
Bispecific antibody with enhanced FVIII cofactor function substitution activity
|
|
CA3032581A1
(en)
|
2016-08-01 |
2018-02-08 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
WO2018026942A1
(en)
*
|
2016-08-02 |
2018-02-08 |
Merrimack Pharmaceuticals, Inc. |
Heteromeric polypeptides
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
IL264626B
(en)
|
2016-08-05 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
A preparation for the prevention or treatment of diseases related to il-8
|
|
BR112019002394B1
(en)
|
2016-08-10 |
2021-12-21 |
Ajou University Industry-Academic Cooperation Foundation |
HETERODIMERIC PROTEIN FLUTED WITH CF AND ITS USE
|
|
JP7093767B2
(en)
|
2016-08-11 |
2022-06-30 |
ジェネンテック， インコーポレイテッド |
Pyrrolobenzodiazepine prodrug and its antibody conjugate
|
|
EP3502250B1
(en)
|
2016-08-22 |
2024-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Gene-modified rodent expressing human gpc3 polypeptide
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN109689682B
(en)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
Complement factor-based affinity chromatography
|
|
ES2958593T3
(en)
|
2016-09-23 |
2024-02-12 |
Hoffmann La Roche |
Uses of IL-13 antagonists for the treatment of atopic dermatitis
|
|
CN109790215B
(en)
|
2016-09-29 |
2023-06-30 |
北京韩美药品有限公司 |
Heterodimeric immunoglobulin constructs and methods for their preparation
|
|
EP3519820B1
(en)
|
2016-09-30 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Spr-based dual-binding assay for the functional analysis of multispecific molecules
|
|
PL3519437T3
(en)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against p95her2
|
|
JP7050770B2
(en)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Method for preparing antibody drug conjugate
|
|
AU2017340504A1
(en)
|
2016-10-05 |
2019-04-11 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
|
WO2018067879A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma Inc. |
Alk4:actriib heteromultimers and uses thereof
|
|
US11267865B2
(en)
*
|
2016-10-05 |
2022-03-08 |
Acceleron Pharma Inc. |
Variant ActRIIB proteins and uses thereof
|
|
JP7579056B2
(en)
|
2016-10-06 |
2024-11-07 |
ジェネンテック， インコーポレイテッド |
Therapeutic and diagnostic methods for cancer
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
JP7142630B2
(en)
|
2016-10-14 |
2022-09-27 |
ゼンコア インコーポレイテッド |
IL15/IL15Rα heterodimeric FC-fusion protein
|
|
KR20240000650A
(en)
|
2016-10-19 |
2024-01-02 |
인벤라 인코포레이티드 |
Antibody constructs
|
|
CN110267678A
(en)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
Anti-MIC antibodies and methods of use
|
|
WO2018083126A1
(en)
|
2016-11-01 |
2018-05-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
CN110312523B
(en)
|
2016-11-08 |
2024-04-26 |
齐鲁皮吉特湾生物治疗有限公司 |
Anti-PD1 and anti-CTLA4 antibodies
|
|
US11013785B2
(en)
|
2016-11-10 |
2021-05-25 |
Keros Therapeutics, Inc. |
Activin receptor type IIA variants and methods of use thereof
|
|
MA46753A
(en)
|
2016-11-14 |
2019-09-18 |
Amgen Inc |
BISPECIFIC OR BIPARATOPIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
CA3042435A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
TW201829463A
(en)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
anti-HLA-G antibody and use thereof
|
|
PE20191080A1
(en)
|
2016-11-18 |
2019-08-20 |
Beijing Hanmi Pharmaceutical Co Ltd |
STRUCTURAL HETERODIMERIC BIESPECIFIC ANTIBODY OF ANTI-PD-1 / ANTI-HER2 NATURAL ANTIBODY AND METHOD TO PREPARE THE SAME
|
|
JOP20190100A1
(en)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
Anti-gitr antigen-binding proteins and methods of use thereof
|
|
PE20200012A1
(en)
|
2016-11-23 |
2020-01-06 |
Bioverativ Therapeutics Inc |
MONO- AND BI-SPECIFIC ANTIBODIES THAT BIND TO COAGULATION FACTOR IX AND COAGULATION FACTOR X
|
|
KR102645073B1
(en)
|
2016-12-07 |
2024-03-11 |
제넨테크, 인크. |
Anti-tau antibodies and methods of using the same
|
|
EP3551220B1
(en)
|
2016-12-07 |
2025-01-29 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
CN110114674B
(en)
|
2016-12-13 |
2023-05-09 |
豪夫迈·罗氏有限公司 |
Method for determining the presence of a target antigen in a tumor sample
|
|
CN117752798A
(en)
|
2016-12-19 |
2024-03-26 |
豪夫迈·罗氏有限公司 |
Combination therapy with targeted 4-1BB (CD137) agonists
|
|
EP3559034B1
(en)
|
2016-12-20 |
2020-12-02 |
H. Hoffnabb-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
|
CN110088291A
(en)
|
2016-12-21 |
2019-08-02 |
豪夫迈·罗氏有限公司 |
Methods for in vitro glycoengineering of antibodies
|
|
AU2017381657B2
(en)
|
2016-12-21 |
2020-07-23 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
|
KR102390246B1
(en)
|
2016-12-21 |
2022-04-22 |
에프. 호프만-라 로슈 아게 |
Reuse of Enzymes for In Vitro Glycoengineering of Antibodies
|
|
JP7215999B2
(en)
|
2016-12-21 |
2023-01-31 |
エフ．ホフマン－ラ ロシュ アーゲー |
Assays for Determining Antibody or Ligand Binding and Function
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
EP3559032A1
(en)
|
2016-12-23 |
2019-10-30 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
MA47200A
(en)
|
2017-01-03 |
2019-11-13 |
Hoffmann La Roche |
BISPECIFIC ANTIGEN BINDING MOLECULES INCLUDING A 20H4.9 ANTI-4-1BB CLONE
|
|
CN117886928A
(en)
|
2017-01-06 |
2024-04-16 |
动量制药公司 |
Compositions and methods related to engineered Fc constructs
|
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN110234355B
(en)
|
2017-02-01 |
2021-11-09 |
浙江时迈药业有限公司 |
Monomeric human IgG1Fc and bispecific antibodies
|
|
WO2018147245A1
(en)
|
2017-02-07 |
2018-08-16 |
第一三共株式会社 |
Anti-gprc5d antibody and molecule containing same
|
|
KR20190118172A
(en)
|
2017-02-08 |
2019-10-17 |
드래곤플라이 쎄라퓨틱스, 인크. |
Multispecific Binding Proteins for Activation of Natural Killer Cells and Their Therapeutic Uses in Cancer Treatment
|
|
EP3579876A4
(en)
*
|
2017-02-10 |
2020-11-18 |
Dragonfly Therapeutics, Inc. |
Proteins binding bcma, nkg2d and cd16
|
|
US10738131B2
(en)
|
2017-02-10 |
2020-08-11 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
|
CN110945021B
(en)
|
2017-02-10 |
2025-09-12 |
根马布私人有限公司 |
Polypeptide variants and their uses
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
JP7685821B2
(en)
|
2017-02-20 |
2025-05-30 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Proteins that bind to Her2, NKG2D and CD16
|
|
EP3586872A4
(en)
|
2017-02-24 |
2020-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
PHARMACEUTICAL COMPOSITION, ANTIG-BINDING MOLECULES, TREATMENT METHODS AND SCREENING METHODS
|
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
US11685776B2
(en)
|
2017-03-02 |
2023-06-27 |
Novartis Ag |
Engineered heterodimeric proteins
|
|
IL322509A
(en)
|
2017-03-09 |
2025-10-01 |
Genmab As |
Antibodies against pd-l1
|
|
PE20191360A1
(en)
|
2017-03-10 |
2019-10-01 |
Hoffmann La Roche |
METHOD TO PRODUCE MULTI-SPECIFIC ANTIBODIES
|
|
MA49279A
(en)
|
2017-03-22 |
2020-02-05 |
Hoffmann La Roche |
ANTIBODY COMPOSITIONS OPTIMIZED FOR THE TREATMENT OF EYE DISORDERS
|
|
KR102715397B1
(en)
|
2017-03-22 |
2024-10-10 |
아센디스 파마 에이에스 |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
|
CN110382542B
(en)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
Bispecific antigen-binding molecules targeting co-stimulatory TNF receptors
|
|
EP3601345A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
|
US20200270359A1
(en)
|
2017-03-31 |
2020-08-27 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
KR20260006707A
(en)
|
2017-03-31 |
2026-01-13 |
메뤼스 엔.페. |
Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
|
|
KR102629905B1
(en)
|
2017-04-01 |
2024-01-30 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
|
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
WO2018187227A1
(en)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
WO2018184964A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
WO2018184966A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Antibodies binding to steap-1
|
|
EP3606956B1
(en)
|
2017-04-04 |
2024-07-31 |
F. Hoffmann-La Roche AG |
Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
|
|
EP3606955B1
(en)
|
2017-04-05 |
2024-11-06 |
F. Hoffmann-La Roche AG |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
EP4112644A1
(en)
|
2017-04-05 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Anti-lag3 antibodies
|
|
TW202515920A
(en)
|
2017-04-11 |
2025-04-16 |
美商因荷布瑞克斯生物科學公司 |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
AU2018250875A1
(en)
|
2017-04-13 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
|
|
US20190078160A1
(en)
|
2017-04-21 |
2019-03-14 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
|
JOP20190248A1
(en)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
Trem2 antigen binding proteins and uses thereof
|
|
SG10201913582XA
(en)
|
2017-04-26 |
2020-02-27 |
Eureka Therapeutics Inc |
Constructs specifically recognizing glypican 3 and uses thereof
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
AU2018271157C1
(en)
|
2017-05-17 |
2021-11-18 |
Merus N.V. |
Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
|
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
EP3630829A1
(en)
|
2017-06-02 |
2020-04-08 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
JP2020522543A
(en)
|
2017-06-07 |
2020-07-30 |
ゲンマブ ビー．ブイ． |
Therapeutic antibody based on a mutated IgG hexamer
|
|
UY37758A
(en)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
|
|
US11312783B2
(en)
|
2017-06-22 |
2022-04-26 |
Novartis Ag |
Antibody molecules to CD73 and uses thereof
|
|
KR20200022447A
(en)
|
2017-06-27 |
2020-03-03 |
노파르티스 아게 |
Dosage regimens of anti-TIM-3 antibodies and uses thereof
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
AR112603A1
(en)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
BIS SPECIFIC ANTIBODIES CONTROL POINT INHIBITORS
|
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
KR20200031659A
(en)
|
2017-07-20 |
2020-03-24 |
노파르티스 아게 |
Dosage regimen of anti-LAG-3 antibody and use thereof
|
|
CA3069469A1
(en)
|
2017-07-21 |
2019-01-24 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
KR102670957B1
(en)
|
2017-07-26 |
2024-05-31 |
포티 세븐, 인코포레이티드 |
Anti-SIRP-alpha antibodies and related methods
|
|
CA3071211A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
DK3665198T3
(en)
|
2017-08-09 |
2025-04-28 |
Merus Nv |
ANTIBODIES THAT BINDING EGFR AND CMET
|
|
AU2018316343B2
(en)
|
2017-08-11 |
2025-06-12 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
|
EP3672986A1
(en)
|
2017-08-22 |
2020-07-01 |
Sanabio, LLC |
Soluble interferon receptors and uses thereof
|
|
IL273592B2
(en)
|
2017-09-29 |
2025-11-01 |
Chugai Pharmaceutical Co Ltd |
A multispecific antigen-binding molecule with activity that replaces the function of a cofactor for blood coagulation factor VIII (FVIII), and a pharmaceutical formulation containing the molecule as an active ingredient
|
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
|
MX2020003497A
(en)
|
2017-10-20 |
2020-07-22 |
Hoffmann La Roche |
Method for generating multispecific antibodies from monospecific antibodies.
|
|
KR102831164B1
(en)
|
2017-10-30 |
2025-07-07 |
에프. 호프만-라 로슈 아게 |
Method for in vivo production of multispecific antibodies from monospecific antibodies
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
MA50505A
(en)
|
2017-11-01 |
2020-09-09 |
Hoffmann La Roche |
2 + 1 BISPECIFIC ANTIBODIES (CONTORSBODIES)
|
|
CN111246884A
(en)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
Novel Antigen Binding Molecules Containing Trimers of TNF Family Ligands
|
|
CA3079129C
(en)
|
2017-11-01 |
2023-02-28 |
F. Hoffmann-La Roche Ag |
Trifab-contorsbody
|
|
JPWO2019088143A1
(en)
|
2017-11-01 |
2020-11-12 |
中外製薬株式会社 |
Antibody variants and isoforms with reduced bioactivity
|
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
|
MX2020004573A
(en)
|
2017-11-01 |
2020-09-25 |
Hoffmann La Roche |
Combination therapy with targeted ox40 agonists.
|
|
ES2984919T3
(en)
|
2017-11-06 |
2024-10-31 |
Hoffmann La Roche |
Diagnostic and therapeutic procedures for cancer
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US11312770B2
(en)
|
2017-11-08 |
2022-04-26 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
EP4428147A3
(en)
|
2017-11-09 |
2024-10-30 |
Keros Therapeutics, Inc. |
Activin receptor type iia variants and methods of use thereof
|
|
CN111556895B
(en)
|
2017-11-14 |
2024-09-13 |
中外制药株式会社 |
Anti-C1S antibodies and methods of use
|
|
CA3081602A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
AU2018371114A1
(en)
|
2017-11-21 |
2020-05-07 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
JP7765181B2
(en)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
Modified IL-2 FC fusion proteins
|
|
CN111527107B
(en)
|
2017-12-21 |
2024-10-01 |
豪夫迈·罗氏有限公司 |
Antibodies that bind to HLA-A2/WT1
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
|
EP3728327A1
(en)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
AU2018396964C1
(en)
|
2017-12-28 |
2024-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against PD-L1
|
|
SG11202004158QA
(en)
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
|
WO2019129677A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Anti-vegf antibodies and methods of use
|
|
MX2020007077A
(en)
|
2018-01-04 |
2020-10-28 |
Iconic Therapeutics Inc |
ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND RELATED METHODS.
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN-BINDING CONSTRUCTS AND GENERALLY MODIFIED T-CELLS FOR THE TREATMENT OF DISEASES
|
|
WO2019140320A1
(en)
|
2018-01-12 |
2019-07-18 |
Genzyme Corporation |
Methods for the quantitation of polypeptides
|
|
CN111699200B
(en)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
Single domain antibodies against PD-1 and variants thereof
|
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
EP3743440A1
(en)
|
2018-01-24 |
2020-12-02 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
US11472874B2
(en)
|
2018-01-31 |
2022-10-18 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US20200354457A1
(en)
|
2018-01-31 |
2020-11-12 |
Hoffmann-La Roche Inc. |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
JP2021511782A
(en)
|
2018-01-31 |
2021-05-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Stabilized immunoglobulin domain
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
CN119733046A
(en)
|
2018-02-06 |
2025-04-01 |
豪夫迈·罗氏有限公司 |
Treatment of eye diseases
|
|
WO2019153200A1
(en)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof
|
|
DK3749346T3
(en)
|
2018-02-08 |
2024-09-09 |
Dragonfly Therapeutics Inc |
ANTIBODY VARIABLE DOMAIN COMBINATIONS TARGETING THE NKG2D RECEPTOR
|
|
CN112040971A
(en)
|
2018-02-08 |
2020-12-04 |
蜻蜓疗法股份有限公司 |
Combination cancer therapy involving multispecific binding proteins that activate natural killer cells
|
|
CR20200391A
(en)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
|
JP7418337B2
(en)
|
2018-02-09 |
2024-01-19 |
ジェネンテック， インコーポレイテッド |
Treatment and diagnosis of mast cell-mediated inflammatory diseases
|
|
TWI829667B
(en)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
Antibodies binding to gprc5d
|
|
JP2021512624A
(en)
|
2018-02-11 |
2021-05-20 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
Anti-PD-1 / anti-VEGF natural antibody structure-like heterodimer type bispecific antibody and its production
|
|
WO2019160007A1
(en)
|
2018-02-14 |
2019-08-22 |
中外製薬株式会社 |
Antigen-binding molecule and combination
|
|
TW201942134A
(en)
|
2018-02-20 |
2019-11-01 |
美商蜻蜓醫療公司 |
Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
|
|
WO2019175198A2
(en)
|
2018-03-12 |
2019-09-19 |
Genmab A/S |
Antibodies
|
|
TWI841551B
(en)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
Combination therapy with targeted 4-1bb (cd137) agonists
|
|
AU2019236372B2
(en)
|
2018-03-13 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
CN112119090B
(en)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use
|
|
EP3775184B1
(en)
|
2018-03-29 |
2025-12-10 |
F. Hoffmann-La Roche AG |
Modulating lactogenic activity in mammalian cells
|
|
EP3774917B1
(en)
|
2018-03-30 |
2025-10-29 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
|
JP7104458B2
(en)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
Lymphocyte activation gene-3 (LAG-3) -binding antibody and its use
|
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
TW202011029A
(en)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
Methods for detecting and quantifying FGF21
|
|
KR20200140878A
(en)
|
2018-04-09 |
2020-12-16 |
암젠 인크 |
Growth differentiation factor 15 fusion protein
|
|
CA3096123A1
(en)
|
2018-04-11 |
2019-10-17 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
SG11202007961QA
(en)
|
2018-04-13 |
2020-09-29 |
Hoffmann La Roche |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
MA52289A
(en)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
FC HETERODIMERUS IL-15 / IL-15RA FUSION PROTEINS AND THEIR USES
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
WO2019204646A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
AR115052A1
(en)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM
|
|
CN112867734A
(en)
|
2018-04-18 |
2021-05-28 |
Xencor股份有限公司 |
PD-1 targeting heterodimeric fusion proteins comprising an IL-15/IL-15Ra Fc fusion protein and a PD-1 antigen binding domain and uses thereof
|
|
AR114789A1
(en)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
MA52485A
(en)
|
2018-05-03 |
2021-03-10 |
Genmab Bv |
COMBINATIONS OF ANTIBODY VARIANTS AND ASSOCIATED USES
|
|
CN112166196A
(en)
|
2018-05-18 |
2021-01-01 |
豪夫迈·罗氏有限公司 |
Targeted intracellular delivery of large nucleic acids
|
|
JP2021525243A
(en)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Compositions and Methods for Promoting Killing of Target Cells by NK Cells
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
MX2020011828A
(en)
|
2018-05-25 |
2021-02-09 |
Alector Llc |
SIGNAL REGULATORY ALPHA PROTEIN ANTIBODIES (SIRPA) AND METHODS OF USE THEREOF.
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US11492409B2
(en)
|
2018-06-01 |
2022-11-08 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
TWI851577B
(en)
|
2018-06-07 |
2024-08-11 |
美商思進公司 |
Camptothecin conjugates
|
|
TWI848953B
(en)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
Multi-specific binding proteins for cancer treatment
|
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
|
CN112469440B
(en)
|
2018-06-18 |
2024-09-06 |
优瑞科生物技术公司 |
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
|
|
PE20210418A1
(en)
|
2018-06-19 |
2021-03-08 |
Atarga Llc |
COMPLEMENT COMPONENT 5 ANTIBODY MOLECULES AND THEIR USES
|
|
JP7513530B2
(en)
|
2018-06-22 |
2024-07-09 |
ジェンマブ ホールディング ビー．ブイ． |
Anti-CD37 and Anti-CD20 Antibodies, Compositions, and Methods of Use Thereof
|
|
CN112384532B
(en)
|
2018-06-29 |
2025-01-10 |
艾利妥 |
Anti-SIRP-β1 antibodies and methods of use thereof
|
|
CN112955465A
(en)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
anti-TCR antibody molecules and uses thereof
|
|
WO2020007817A1
(en)
|
2018-07-04 |
2020-01-09 |
F. Hoffmann-La Roche Ag |
Novel bispecific agonistic 4-1bb antigen binding molecules
|
|
AR116109A1
(en)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
|
|
WO2020012038A1
(en)
|
2018-07-13 |
2020-01-16 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
|
MX2019012869A
(en)
|
2018-07-13 |
2020-01-23 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof.
|
|
MA53122A
(en)
|
2018-07-13 |
2021-05-19 |
Genmab As |
CD38 ANTIBODY VARIANTS AND THEIR USES
|
|
US11214619B2
(en)
|
2018-07-20 |
2022-01-04 |
Surface Oncology, Inc. |
Anti-CD112R compositions and methods
|
|
CA3105891A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
MX2021000827A
(en)
|
2018-08-03 |
2021-03-25 |
Chugai Pharmaceutical Co Ltd |
ANTIGEN-BINDING MOLECULE CONTAINING TWO ANTIGEN-BINDING DOMAINS THAT ARE LINKED TO EACH OTHER.
|
|
AU2019318083A1
(en)
|
2018-08-08 |
2021-02-25 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
|
|
KR20250112921A
(en)
|
2018-08-08 |
2025-07-24 |
드래곤플라이 쎄라퓨틱스, 인크. |
Proteins binding nkg2d, cd16 and a tumor-associated antigen
|
|
EA202091888A1
(en)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
|
|
MA50586A
(en)
|
2018-08-09 |
2020-09-16 |
Regeneron Pharma |
METHODS FOR EVALUATING THE BINDING AFFINITY OF AN ANTIBODY VARIANT TO THE NEONATAL FC RECEPTOR
|
|
EP3835321A4
(en)
|
2018-08-10 |
2022-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CD137 ANTIGEN BINDING MOLECULE AND USE THEREOF
|
|
TW202021618A
(en)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
Anti-il1rap antibodies and methods of use thereof
|
|
JP7523349B2
(en)
|
2018-08-29 |
2024-07-26 |
中外製薬株式会社 |
Antibody half molecules and methods for inhibiting homodimer formation of antibody half molecules
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
JP7482853B2
(en)
|
2018-09-10 |
2024-05-14 |
ジェネンテック， インコーポレイテッド |
Affinity capillary electrophoresis system and method
|
|
US11573226B2
(en)
|
2018-09-10 |
2023-02-07 |
Genentech, Inc. |
Systems and methods for affinity capillary electrophoresis
|
|
TWI841595B
(en)
|
2018-09-10 |
2024-05-11 |
大陸商南京傳奇生物科技有限公司 |
Single-domain antibodies against cd33 and constructs thereof
|
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
EP3856778A1
(en)
|
2018-09-24 |
2021-08-04 |
The Medical College of Wisconsin, Inc. |
System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
|
|
MX2021003548A
(en)
|
2018-10-01 |
2021-05-27 |
Hoffmann La Roche |
Bispecific antigen binding molecules comprising anti-fap clone 212.
|
|
CN112654641A
(en)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
Bispecific antigen binding molecules with trivalent binding to CD40
|
|
AU2019355971B2
(en)
|
2018-10-03 |
2025-05-08 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
|
MA53812A
(en)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIES
|
|
JP2022512684A
(en)
|
2018-10-11 |
2022-02-07 |
インヒブルクス インコーポレイテッド |
B7H3 single domain antibody and therapeutic composition thereof
|
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
CN113518647A
(en)
|
2018-10-11 |
2021-10-19 |
印希比股份有限公司 |
5T4 single domain antibodies and therapeutic compositions thereof
|
|
EP3864049A1
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Pd-1 single domain antibodies and therapeutic compositions thereof
|
|
US11377477B2
(en)
|
2018-10-12 |
2022-07-05 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
EP3870598A1
(en)
|
2018-10-23 |
2021-09-01 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
MX2021004774A
(en)
|
2018-10-29 |
2021-08-24 |
Hoffmann La Roche |
Antibody formulation.
|
|
CN113454111A
(en)
|
2018-11-06 |
2021-09-28 |
健玛保 |
Antibody formulation
|
|
BR112021008795A2
(en)
|
2018-11-13 |
2021-08-31 |
Compass Therapeutics Llc |
MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND THEIR USES
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
CA3121699A1
(en)
|
2018-12-05 |
2020-06-11 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
|
CA3119798A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
|
JP2022513198A
(en)
|
2018-12-10 |
2022-02-07 |
ジェネンテック， インコーポレイテッド |
Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins
|
|
AU2019402097A1
(en)
|
2018-12-17 |
2021-06-10 |
Revitope Limited |
Twin immune cell engager
|
|
TWI874341B
(en)
|
2018-12-18 |
2025-03-01 |
美商健生生物科技公司 |
Methods of producing heterodimeric antibodies
|
|
EP3897637A1
(en)
|
2018-12-20 |
2021-10-27 |
Novartis AG |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3897647B1
(en)
|
2018-12-20 |
2023-11-01 |
Novartis AG |
Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
|
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
AR117327A1
(en)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
ANTI-CD96 ANTIBODIES AND METHODS OF USE OF THEM
|
|
AR117453A1
(en)
|
2018-12-20 |
2021-08-04 |
Genentech Inc |
CF OF MODIFIED ANTIBODIES AND METHODS TO USE THEM
|
|
CN113621062B
(en)
|
2018-12-21 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
Antibodies that bind to CD3
|
|
EP3898683A1
(en)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
EP3898673A1
(en)
|
2018-12-21 |
2021-10-27 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
|
US11608376B2
(en)
|
2018-12-21 |
2023-03-21 |
Hoffmann-La Roche Inc. |
Tumor-targeted agonistic CD28 antigen binding molecules
|
|
JP2022515424A
(en)
|
2018-12-24 |
2022-02-18 |
サノフイ |
Multispecific binding protein with mutated fab domain
|
|
CA3124770A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
|
US20220073630A1
(en)
|
2018-12-28 |
2022-03-10 |
Hoffmann-La Roche, Inc. |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
EP3903102B1
(en)
|
2018-12-30 |
2023-04-12 |
F. Hoffmann-La Roche AG |
Ph-gradient spr-based binding assay
|
|
KR20210113261A
(en)
|
2019-01-04 |
2021-09-15 |
리졸브 테라퓨틱스, 엘엘씨 |
Treatment of Sjogren's Disease Using Nuclease Fusion Proteins
|
|
PH12021551475A1
(en)
*
|
2019-01-07 |
2022-05-02 |
Shattuck Labs Inc |
Heterodimeric proteins for modulating gamma delta t cells
|
|
TWI852977B
(en)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
Prostate neoantigens and their uses
|
|
JP7303314B2
(en)
|
2019-01-18 |
2023-07-04 |
ヤンセン バイオテツク，インコーポレーテツド |
GPRC5D chimeric antigen receptor and cells expressing it
|
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
ES2982474T3
(en)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-1,6-dione derivatives and their uses
|
|
CN113490528B
(en)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
CN114026122B
(en)
|
2019-02-21 |
2024-12-31 |
马伦戈治疗公司 |
Multifunctional molecules that bind to T cell-associated cancer cells and their uses
|
|
CN114127113A
(en)
|
2019-02-21 |
2022-03-01 |
马伦戈治疗公司 |
Multifunctional molecules binding to calreticulin and uses thereof
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
|
CA3130628A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
PH12021552030A1
(en)
|
2019-02-26 |
2022-08-15 |
Janssen Biotech Inc |
Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
|
|
BR112021016955A2
(en)
|
2019-03-01 |
2021-11-23 |
Xencor Inc |
Composition, nucleic acid composition, expression vector composition, expression vector, host cell, methods of producing an ectonucleotide pyrophosphatase/phosphodiesterase family 3 member binding domain and of treating a cancer, anti-enpp3 antibody , and, heterodimeric antibody
|
|
WO2020180811A1
(en)
|
2019-03-04 |
2020-09-10 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-sirp-alpha antibodies
|
|
KR20250143873A
(en)
|
2019-03-08 |
2025-10-02 |
제넨테크, 인크. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
|
EP3938403A1
(en)
|
2019-03-14 |
2022-01-19 |
F. Hoffmann-La Roche AG |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
|
WO2020200941A1
(en)
|
2019-03-29 |
2020-10-08 |
F. Hoffmann-La Roche Ag |
Spr-based binding assay for the functional analysis of multivalent molecules
|
|
CN113677701B
(en)
|
2019-03-29 |
2025-02-07 |
豪夫迈·罗氏有限公司 |
Methods for producing affinity-binding multispecific antibodies
|
|
EP3946593A1
(en)
|
2019-03-29 |
2022-02-09 |
Atarga, LLC |
Anti fgf23 antibody
|
|
CN113677403B
(en)
|
2019-04-12 |
2024-12-27 |
豪夫迈·罗氏有限公司 |
Bispecific antigen-binding molecules comprising lipocalin muteins
|
|
MX2021012692A
(en)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anti-mertk antibodies and their methods of use.
|
|
MX2021012871A
(en)
|
2019-04-25 |
2021-11-17 |
Hoffmann La Roche |
Generation of antibody-derived polypeptides by polypeptide chain exchange.
|
|
MX2021012931A
(en)
|
2019-04-25 |
2021-11-17 |
Hoffmann La Roche |
Activatable therapeutic multispecific polypeptides with extended half-life.
|
|
BR112021020859A2
(en)
|
2019-04-25 |
2022-01-04 |
Hoffmann La Roche |
Polypeptide assemblies, method for generating a polypeptide, heterodimeric polypeptide, first heterodimeric precursor polypeptide, and second heterodimeric precursor polypeptide
|
|
MX2021013220A
(en)
|
2019-05-03 |
2021-12-10 |
Genentech Inc |
METHODS TO REDUCE THE ACTIVITY RATE OF ENZYMATIC HYDROLYSIS IN A COMPOSITION OBTAINED FROM A PURIFICATION PLATFORM.
|
|
EP3966244A1
(en)
|
2019-05-09 |
2022-03-16 |
F. Hoffmann-La Roche AG |
Methods of making antibodies
|
|
WO2020225456A1
(en)
|
2019-05-09 |
2020-11-12 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
EP3969907B1
(en)
|
2019-05-13 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
|
TW202108178A
(en)
|
2019-05-14 |
2021-03-01 |
美商建南德克公司 |
METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT FOLLICULAR LYMPHOMA
|
|
KR20250156861A
(en)
|
2019-05-21 |
2025-11-03 |
노파르티스 아게 |
Cd19 binding molecules and uses thereof
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
CN114173810B
(en)
|
2019-05-21 |
2024-09-06 |
诺华股份有限公司 |
Trispecific binding molecules against BCMA and uses thereof
|
|
AU2020282791A1
(en)
|
2019-05-31 |
2021-12-09 |
ALX Oncology Inc. |
Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
|
|
MX2021015007A
(en)
|
2019-06-10 |
2022-01-31 |
Chugai Pharmaceutical Co Ltd |
ANTI-T CELL ANTIGEN BINDING MOLECULE FOR USE IN COMBINATION WITH A CYTOKINE INHIBITOR.
|
|
AU2020291527A1
(en)
|
2019-06-11 |
2022-01-20 |
Alector Llc |
Anti-Sortilin antibodies for use in therapy
|
|
CN118547004A
(en)
|
2019-06-19 |
2024-08-27 |
豪夫迈·罗氏有限公司 |
Method for generating protein expressing cells by targeted integration using Cre mRNA
|
|
CA3140192A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
MX2021015540A
(en)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
METHOD FOR THE GENERATION OF A CELL THAT EXPRESSES A TRIVALENT ANTIBODY BY MEANS OF THE DIRECTED INTEGRATION OF MULTIPLE EXPRESSION CASSETTES IN A DEFINED ORGANIZATION.
|
|
KR20220010019A
(en)
|
2019-06-19 |
2022-01-25 |
에프. 호프만-라 로슈 아게 |
Methods of Generating Bivalent Bispecific Antibody Expression Cells by Targeted Integration of Multiple Expression Cassettes in Defined Tissues
|
|
BR112021025500A2
(en)
|
2019-06-19 |
2022-02-01 |
Hoffmann La Roche |
Methods for producing a bispecific multivalent antibody and for producing a recombinant mammalian cell, deoxyribonucleic acid, use of a deoxyribonucleic acid, recombinant mammalian cell and composition
|
|
CN117821393A
(en)
|
2019-06-26 |
2024-04-05 |
豪夫迈·罗氏有限公司 |
Mammalian cell lines with SIRT-1 gene knockout
|
|
KR20220025848A
(en)
|
2019-06-26 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
Fusion of antibodies that bind CEA and 4-1BBL
|
|
CN114531878A
(en)
|
2019-06-27 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
Novel ICOS antibodies and tumor-targeted antigen-binding molecules comprising same
|
|
CA3143524A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
AU2020309958A1
(en)
|
2019-07-10 |
2021-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
|
AR119382A1
(en)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
PRE-TARGETING ANTIBODIES AND METHODS OF USE
|
|
AR119393A1
(en)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
ANTIBODIES THAT BIND NKG2D
|
|
CN115175932B
(en)
|
2019-07-16 |
2025-10-31 |
赛诺菲 |
Neutralizing anti-beta amyloid antibodies for the treatment of alzheimer's disease
|
|
CR20220078A
(en)
|
2019-07-31 |
2022-06-24 |
Alector Llc |
ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF
|
|
JP2022543553A
(en)
|
2019-07-31 |
2022-10-13 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Antibody that binds to GPRC5D
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
TWI780464B
(en)
|
2019-08-06 |
2022-10-11 |
香港商新旭生技股份有限公司 |
Antibodies that bind to pathological tau species and uses thereof
|
|
WO2021026409A1
(en)
|
2019-08-08 |
2021-02-11 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
|
TW202120534A
(en)
|
2019-08-13 |
2021-06-01 |
美商安進公司 |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
JP7792330B2
(en)
|
2019-09-03 |
2025-12-25 |
アムジエン・インコーポレーテツド |
IL-22 oral, rectal, or other gastrointestinal-related compositions and methods of using same
|
|
WO2021050645A1
(en)
|
2019-09-12 |
2021-03-18 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
TW202126698A
(en)
|
2019-09-18 |
2021-07-16 |
美商建南德克公司 |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
JP2022549218A
(en)
|
2019-09-20 |
2022-11-24 |
ジェネンテック， インコーポレイテッド |
Anti-tryptase antibody medication
|
|
EP4036116A4
(en)
|
2019-09-27 |
2024-01-24 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-vhh domain antibodies and use thereof
|
|
TWI878355B
(en)
|
2019-10-02 |
2025-04-01 |
德商百靈佳殷格翰國際股份有限公司 |
Multi-specific binding proteins for cancer treatment
|
|
TW202128757A
(en)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins with improved properties
|
|
CN118557750A
(en)
|
2019-10-18 |
2024-08-30 |
基因泰克公司 |
Methods of treating diffuse large B-cell lymphoma using anti-CD79b immunoconjugates
|
|
BR112022007179A2
(en)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
TIM-3 INHIBITORS AND USES THEREOF
|
|
IL292347A
(en)
|
2019-10-21 |
2022-06-01 |
Novartis Ag |
Combination therapies with venetoclax and tim-3 inhibitors
|
|
AU2020379735A1
(en)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharmaceuticals, Inc. |
N-terminal SCFV multispecific binding molecules
|
|
US20220411529A1
(en)
|
2019-11-06 |
2022-12-29 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
|
EP4058593A4
(en)
|
2019-11-12 |
2023-11-15 |
Foundation Medicine, Inc. |
METHOD FOR DETECTING A FUSION GENE CODING A NEOANTIGEN
|
|
WO2021094508A1
(en)
|
2019-11-15 |
2021-05-20 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in aqueous protein solutions
|
|
EP4061837A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
|
|
CA3160438A1
(en)
|
2019-11-19 |
2021-05-27 |
Amgen Inc. |
Novel multispecific antibody format
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
BR112022008817A2
(en)
|
2019-11-27 |
2022-07-26 |
Alx Oncology Inc |
COMBINED THERAPIES FOR CANCER TREATMENT
|
|
CN113135996A
(en)
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
Bispecific antibody and application thereof
|
|
EP4072584B1
(en)
|
2019-12-13 |
2026-01-28 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
|
PE20221506A1
(en)
|
2019-12-17 |
2022-10-04 |
Amgen Inc |
DUAL INTERLEUKIN-2/TNF RECEPTOR AGONIST FOR USE IN THERAPY
|
|
MX2022006578A
(en)
|
2019-12-17 |
2022-07-04 |
Pfizer |
Antibodies specific for cd47, pd-l1, and uses thereof.
|
|
US11739142B2
(en)
|
2019-12-18 |
2023-08-29 |
Hoffmann-La Roche Inc. |
Bispecific anti-CCL2 antibodies
|
|
CR20220256A
(en)
|
2019-12-18 |
2022-08-31 |
Hoffmann La Roche |
ANTIBODIES THAT BIND HLA-A2/MAGE-A4
|
|
IL293889A
(en)
|
2019-12-20 |
2022-08-01 |
Novartis Ag |
Uses of antitgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
CN114846024A
(en)
|
2019-12-20 |
2022-08-02 |
豪夫迈·罗氏有限公司 |
IL-37 fusion proteins and uses thereof
|
|
US12091440B2
(en)
|
2019-12-20 |
2024-09-17 |
Regeneron Pharmaceuticals, Inc. |
IL2 and peptide-MHC complex fusion proteins and methods of use thereof
|
|
WO2021133723A2
(en)
|
2019-12-23 |
2021-07-01 |
Genentech, Inc. |
Apolipoprotein l1-specific antibodies and methods of use
|
|
MY202559A
(en)
|
2019-12-27 |
2024-05-08 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibody and use thereof
|
|
US11913945B2
(en)
|
2020-01-02 |
2024-02-27 |
Hoffmann-La Roche Inc. |
Method for determining the amount of a therapeutic antibody in the brain
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
CN114929734A
(en)
|
2020-01-09 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
Novel antigen binding molecules comprising 4-1BBL trimers
|
|
CN110818795B
(en)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
anti-TIGIT antibodies and methods of use
|
|
KR20220129003A
(en)
|
2020-01-15 |
2022-09-22 |
에프. 호프만-라 로슈 아게 |
Methods for Reducing Impurities from Recombinant Protein Manufacturing Processes
|
|
BR112022013553A2
(en)
|
2020-01-16 |
2022-09-06 |
Genmab As |
PHARMACEUTICAL COMPOSITION, ANTIBODY, AND METHOD TO TREAT A DISEASE
|
|
WO2021146636A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
WO2021144657A1
(en)
|
2020-01-17 |
2021-07-22 |
Novartis Ag |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
WO2021160154A1
(en)
|
2020-02-10 |
2021-08-19 |
上海诗健生物科技有限公司 |
Cldn18.2 antibody and use thereof
|
|
KR20220140786A
(en)
|
2020-02-10 |
2022-10-18 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
Claudin 18.2 Antibodies and Their Uses
|
|
TWI895351B
(en)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
Anti-CD137 antigen binding molecules for the treatment of cancer
|
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
MX2022010549A
(en)
|
2020-02-26 |
2022-11-16 |
Biograph 55 Inc |
C19 c38 bispecific antibodies.
|
|
MX2022010685A
(en)
|
2020-02-27 |
2022-09-23 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells.
|
|
PE20230252A1
(en)
|
2020-03-13 |
2023-02-07 |
Genentech Inc |
ANTI-INTERLEUKIN-33 ANTIBODIES AND ITS USES FOR THEM
|
|
AU2021236906A1
(en)
|
2020-03-18 |
2022-08-18 |
Genmab A/S |
Antibodies binding to B7H4
|
|
KR20250074688A
(en)
|
2020-03-19 |
2025-05-27 |
제넨테크, 인크. |
Isoform-selective anti-tgf-beta antibodies and methods of use
|
|
MX2022011752A
(en)
|
2020-03-24 |
2022-10-18 |
Genentech Inc |
Tie2-binding agents and methods of use.
|
|
CA3173162A1
(en)
|
2020-03-25 |
2021-09-30 |
Eli Lilly And Company |
Multispecific binding proteins and methods of developing the same
|
|
US12098365B2
(en)
|
2020-03-26 |
2024-09-24 |
Genentech, Inc. |
Modified mammalian cells
|
|
EP4126241A1
(en)
|
2020-03-27 |
2023-02-08 |
Novartis AG |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
|
KR20220160598A
(en)
|
2020-03-30 |
2022-12-06 |
고쿠리츠다이가쿠호진 미에다이가쿠 |
bispecific antibody
|
|
AR121706A1
(en)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES
|
|
WO2021201202A1
(en)
|
2020-04-02 |
2021-10-07 |
中外製薬株式会社 |
Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules
|
|
JP2023520515A
(en)
|
2020-04-03 |
2023-05-17 |
ジェネンテック， インコーポレイテッド |
Therapeutic and diagnostic methods for cancer
|
|
MX2022012541A
(en)
|
2020-04-15 |
2022-11-07 |
Hoffmann La Roche |
IMMUNOCONJUGATES.
|
|
AU2021257848A1
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
KR20230028242A
(en)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
Multifunctional molecules that bind to T cell-associated cancer cells and their uses
|
|
CR20220531A
(en)
|
2020-04-24 |
2022-11-28 |
Hoffmann La Roche |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
|
AU2021259861A1
(en)
|
2020-04-24 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-CD79b immunoconjugates
|
|
JP2023523450A
(en)
|
2020-04-28 |
2023-06-05 |
ジェネンテック， インコーポレイテッド |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
US20230172923A1
(en)
|
2020-04-30 |
2023-06-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
|
EP4143236A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Engineered immunoglobulins
|
|
WO2021225892A1
(en)
|
2020-05-03 |
2021-11-11 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
|
EP4146271A4
(en)
|
2020-05-06 |
2024-09-04 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and clec12a
|
|
US12435154B2
(en)
|
2020-05-08 |
2025-10-07 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20
|
|
CN115551540A
(en)
|
2020-05-11 |
2022-12-30 |
豪夫迈·罗氏有限公司 |
Combination therapy using modified PBMCs and immunoconjugates
|
|
IL298007A
(en)
|
2020-05-12 |
2023-01-01 |
Regeneron Pharma |
Novel il10 agonists and methods of using them
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
CN115605184A
(en)
|
2020-05-15 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
Prevention of visible particle formation in parenteral protein solutions
|
|
US20230192797A1
(en)
|
2020-05-18 |
2023-06-22 |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
Human il-15 mutant and uses thereof
|
|
CN115605185A
(en)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
Use of a chelating agent to prevent the formation of visible particles in parenteral protein solutions
|
|
KR20230012559A
(en)
|
2020-05-19 |
2023-01-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
Binding Molecules for Cancer Treatment
|
|
EP4157461A1
(en)
|
2020-05-29 |
2023-04-05 |
23Andme, Inc. |
Anti-cd200r1 antibodies and methods of use thereof
|
|
MX2022015206A
(en)
|
2020-06-08 |
2023-01-05 |
Hoffmann La Roche |
ANTI-HBV ANTIBODIES AND METHODS OF USE.
|
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
IL298402A
(en)
|
2020-06-19 |
2023-01-01 |
Hoffmann La Roche |
Antibodies binding to cd3 and cd19
|
|
AR122657A1
(en)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
IMMUNE-ACTIVATED FC DOMAIN-BINDING MOLECULES
|
|
CA3185513A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and folr1
|
|
PH12022500027A1
(en)
|
2020-06-19 |
2024-03-25 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
AU2021291002A1
(en)
|
2020-06-19 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Protease-activated T cell bispecific antibodies
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
AU2021292932A1
(en)
|
2020-06-19 |
2023-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-T cell antigen-binding molecule for use in combination with angiogenesis inhibitor
|
|
JP2023531222A
(en)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
ANTI-IL-36 ANTIBODY AND METHODS OF USE THEREOF
|
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
JP7678005B2
(en)
|
2020-06-23 |
2025-05-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Agonistic CD28 antigen-binding molecules targeting Her2
|
|
MX2022016453A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Apoptosis resistant cell lines.
|
|
WO2021260064A1
(en)
|
2020-06-25 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
CN116133689A
(en)
|
2020-07-07 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
Alternative Surfactants as Stabilizers for Therapeutic Protein Formulations
|
|
KR20230037578A
(en)
|
2020-07-10 |
2023-03-16 |
에프. 호프만-라 로슈 아게 |
Antibodies that bind to cancer cells and target radionuclides to those cells
|
|
MX2023000547A
(en)
|
2020-07-16 |
2023-02-13 |
Novartis Ag |
ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES.
|
|
US20230303682A1
(en)
|
2020-07-17 |
2023-09-28 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Methods of Use
|
|
CA3188656A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
BR112023001143A2
(en)
|
2020-07-21 |
2023-02-14 |
Genentech Inc |
CONJUGATE, COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS TO TREAT A DISEASE AND REDUCE THE LEVEL OF A TARGET BRM PROTEIN IN AN INDIVIDUAL
|
|
US20230293680A1
(en)
|
2020-07-23 |
2023-09-21 |
Genmab B.V. |
A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
KR20230048059A
(en)
|
2020-07-31 |
2023-04-10 |
추가이 세이야쿠 가부시키가이샤 |
Pharmaceutical composition comprising cells expressing chimeric receptors
|
|
WO2022029573A1
(en)
|
2020-08-03 |
2022-02-10 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN116194477A
(en)
|
2020-08-06 |
2023-05-30 |
生物技术欧洲股份公司 |
Binder for coronavirus S protein
|
|
KR20230166150A
(en)
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
Anti-cd28 compositions
|
|
CA3190766A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
CN116249718A
(en)
|
2020-08-26 |
2023-06-09 |
马伦戈治疗公司 |
Multifunctional molecules binding to calreticulin and uses thereof
|
|
WO2022047046A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Methods of detecting trbc1 or trbc2
|
|
TW202227625A
(en)
|
2020-08-28 |
2022-07-16 |
美商建南德克公司 |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
US20230416371A1
(en)
|
2020-08-28 |
2023-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimer fc polypeptide
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230310599A1
(en)
|
2020-09-02 |
2023-10-05 |
Genmab A/S |
Antibody therapy
|
|
BR112023004296A2
(en)
|
2020-09-10 |
2023-04-04 |
Genmab As |
METHOD FOR TREATING DIFFERENT GRAND B-CELL LYMPHOMA IN A HUMAN INDIVIDUAL
|
|
CN116437956A
(en)
|
2020-09-10 |
2023-07-14 |
健玛保 |
Bispecific antibodies against CD3 and CD20 for the treatment of chronic lymphocytic leukemia
|
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
AU2021342343A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
CA3189883A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
JP2023542289A
(en)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー／エス |
Bispecific antibodies against CD3 and CD20 in combination therapy to treat follicular lymphoma
|
|
AU2021341526A1
(en)
|
2020-09-14 |
2023-04-27 |
IGI Therapeutics SA |
Antibodies that bind to il1rap and uses thereof
|
|
JP2023542079A
(en)
|
2020-09-21 |
2023-10-05 |
ジェネンテック， インコーポレイテッド |
Purification of multispecific antibodies
|
|
CN116391037A
(en)
|
2020-09-24 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
Mammalian cell lines with gene knockouts
|
|
CA3193914A1
(en)
|
2020-10-02 |
2022-04-07 |
Louise KOOPMAN |
Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
|
|
WO2022072882A1
(en)
|
2020-10-02 |
2022-04-07 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US11926667B2
(en)
|
2020-10-13 |
2024-03-12 |
Janssen Biotech, Inc. |
Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
|
|
KR20230091871A
(en)
|
2020-10-20 |
2023-06-23 |
에프. 호프만-라 로슈 아게 |
Combination therapy of a PD-1 axis binding antagonist and a LRRK2 inhibitor
|
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
|
AR123862A1
(en)
|
2020-10-21 |
2023-01-18 |
Boehringer Ingelheim Int |
ANTI-VEGF AND ANTI-TRKB BISPECIFIC BINDING MOLECULES FOR THE TREATMENT OF OCULAR DISEASES
|
|
EP4237003A4
(en)
|
2020-10-28 |
2025-07-09 |
Janssen Biotech Inc |
Compositions and methods for modulating delta-gamma chain-mediated immunity
|
|
EP4237451A1
(en)
|
2020-11-02 |
2023-09-06 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
|
WO2022097061A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
KR20230107305A
(en)
|
2020-11-10 |
2023-07-14 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
Bispecific Antibodies to Claudin 18A2 and CD3 and Uses of Bispecific Antibodies
|
|
JP2023549504A
(en)
|
2020-11-13 |
2023-11-27 |
ノバルティス アーゲー |
Combination therapy with chimeric antigen receptor (CAR) expressing cells
|
|
CN117916261A
(en)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
Combination therapy with FAP-targeted CD40 agonists
|
|
WO2022101088A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Fab high mannose glycoforms
|
|
CN116723861A
(en)
|
2020-12-02 |
2023-09-08 |
上海复宏汉霖生物技术股份有限公司 |
Anti-GARP/TGFβ antibodies and how to use them
|
|
KR20230117169A
(en)
|
2020-12-02 |
2023-08-07 |
알렉터 엘엘씨 |
Methods of Using Anti-Sortilin Antibodies
|
|
CA3197740A1
(en)
|
2020-12-04 |
2022-06-09 |
F. Hoffman-La Roche Ag |
Ph-dependent mutant interleukin-2 polypeptides
|
|
IL303295A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Multispecific antibodies and antibody combinations
|
|
AU2021398385A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
|
KR20230120665A
(en)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
Anti-HLA-G Antibodies and Uses Thereof
|
|
WO2022129313A1
(en)
|
2020-12-18 |
2022-06-23 |
F. Hoffmann-La Roche Ag |
Precursor proteins and kit for targeted therapy
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
MX2023007846A
(en)
|
2021-01-06 |
2023-07-07 |
Hoffmann La Roche |
CO-TREATMENT USING A BISPECIFIC ANTIBODY AGAINST PD1-LAG3 AND A BISPECIFIC ANTIBODY TO CD20 T LYMPHOCYTES.
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
US20240082437A1
(en)
|
2021-01-12 |
2024-03-14 |
Hoffmann-La Roche Inc. |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
|
US20240173442A1
(en)
|
2021-01-13 |
2024-05-30 |
Hoffmann-La Roche Inc. |
Combination therapy
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
MX2023009100A
(en)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Binding agents and methods of using the same.
|
|
JP2024509695A
(en)
|
2021-02-03 |
2024-03-05 |
ジェネンテック， インコーポレイテッド |
Multispecific binding proteolysis platform and methods of use
|
|
CN117794566A
(en)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
Sabei virus binding agent
|
|
US11639396B2
(en)
|
2021-02-16 |
2023-05-02 |
Janssen Biotech, Inc. |
Antibody binding to a linker peptide
|
|
JP2024512240A
(en)
|
2021-02-18 |
2024-03-19 |
エフ． ホフマン－ラ ロシュ アーゲー |
Methods for elucidating complex multistep antibody interactions
|
|
JP7773237B2
(en)
|
2021-02-19 |
2025-11-19 |
シャペロン インク． |
Single domain antibodies against CD47 and uses thereof
|
|
BR112023016706A2
(en)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Antibody or an antigen-binding fragment thereof, nucleic acid molecule, methods for producing an antibody or an antigen-binding fragment thereof and for detecting cluster of differentiation 47 or determining an amount of cluster of differentiation 47 in a sample, and, use of the antibody or an antigen-binding fragment thereof
|
|
CN117440832A
(en)
|
2021-03-03 |
2024-01-23 |
索伦托药业有限公司 |
Antibody-drug conjugates comprising anti-BCMA antibodies
|
|
CN117222663A
(en)
|
2021-03-03 |
2023-12-12 |
蜻蜓疗法股份有限公司 |
Methods of treating cancer using multispecific binding proteins that bind NKG2D, CD16, and tumor-associated antigens
|
|
AU2022231874A1
(en)
|
2021-03-09 |
2023-07-27 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
EP4304724A1
(en)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
KR20230154311A
(en)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Heterodimeric antibodies binding to CD3 and GPC3
|
|
EP4304732A1
(en)
|
2021-03-12 |
2024-01-17 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
CN116964085A
(en)
|
2021-03-12 |
2023-10-27 |
根马布股份公司 |
Non-activating antibody variants
|
|
KR20230156373A
(en)
|
2021-03-15 |
2023-11-14 |
제넨테크, 인크. |
Therapeutic compositions and methods of treating lupus nephritis
|
|
CN116981696A
(en)
|
2021-03-18 |
2023-10-31 |
艾莱克特有限责任公司 |
Anti-TMEM106B antibodies and methods of use
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
US20240166738A1
(en)
|
2021-03-23 |
2024-05-23 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
|
JP2024512035A
(en)
|
2021-03-24 |
2024-03-18 |
ヤンセン バイオテツク，インコーポレーテツド |
Antibodies targeting CD22 and CD79B
|
|
AU2022246275A1
(en)
|
2021-03-26 |
2023-11-09 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
|
IL305847A
(en)
|
2021-03-26 |
2023-11-01 |
Innate Pharma |
Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
|
|
PH12023500022A1
(en)
|
2021-03-29 |
2024-03-11 |
Daiichi Sankyo Co Ltd |
Stable multispecific molecule and use thereof
|
|
WO2022206872A1
(en)
|
2021-03-31 |
2022-10-06 |
江苏恒瑞医药股份有限公司 |
Truncated taci polypeptide and fusion protein and use thereof
|
|
TW202304994A
(en)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
Agonistic anti-il-2r antibodies and methods of use
|
|
TW202304979A
(en)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
|
WO2022216993A2
(en)
|
2021-04-08 |
2022-10-13 |
Marengo Therapeutics, Inc. |
Multifuntional molecules binding to tcr and uses thereof
|
|
WO2022214565A1
(en)
|
2021-04-09 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Process for selecting cell clones expressing a heterologous polypeptide
|
|
AU2022253902A1
(en)
|
2021-04-10 |
2023-11-02 |
Genmab A/S |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
AR125344A1
(en)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
ANTI-C1S ANTIBODY
|
|
IL307501A
(en)
|
2021-04-19 |
2023-12-01 |
Hoffmann La Roche |
Modified mammalian cells
|
|
JP7742892B2
(en)
|
2021-04-23 |
2025-09-22 |
ジェンマブ エー／エス |
Anti-CD70 antibodies, conjugates thereof and methods of using same
|
|
CA3213632A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
WO2022233764A1
(en)
|
2021-05-03 |
2022-11-10 |
UCB Biopharma SRL |
Antibodies
|
|
CN117597365A
(en)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
Multispecific FGF21 receptor agonists and their applications
|
|
BR112023022878A2
(en)
|
2021-05-04 |
2024-01-23 |
Regeneron Pharma |
MULTI-SPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES
|
|
BR112023021089A2
(en)
|
2021-05-07 |
2023-12-12 |
Genmab As |
PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A DISEASE, METHOD FOR TREATING CANCER IN AN INDIVIDUAL, USE OF THE PHARMACEUTICAL COMPOSITION, UNIT DOSAGE FORM, KIT OF PARTS, AND, METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION
|
|
WO2022238481A1
(en)
|
2021-05-11 |
2022-11-17 |
Modiquest B.V. |
Antibodies
|
|
TW202310876A
(en)
|
2021-05-12 |
2023-03-16 |
美商建南德克公司 |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CA3218542A1
(en)
|
2021-05-12 |
2022-11-17 |
Hua Ying |
Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
|
|
CA3216908A1
(en)
|
2021-05-13 |
2022-11-17 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
AR125855A1
(en)
|
2021-05-14 |
2023-08-16 |
Genentech Inc |
TREM2 AGONISTS
|
|
WO2022237882A1
(en)
|
2021-05-14 |
2022-11-17 |
江苏恒瑞医药股份有限公司 |
Antigen-binding molecule
|
|
AR125874A1
(en)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
COMBINATION THERAPIES
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
CN113278071B
(en)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
Anti-human interferon alpha receptor1 monoclonal antibody and application thereof
|
|
AR126009A1
(en)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
CD28 ANTIGEN-BINDING AGONIST MOLECULES THAT TARGET EPCAM
|
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
JP2024521408A
(en)
|
2021-06-09 |
2024-05-31 |
イナート・ファルマ・ソシエテ・アノニム |
Multispecific antibodies binding to CD20, NKP46, CD16 and conjugated to IL-2
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
MX2023014563A
(en)
|
2021-06-09 |
2024-02-08 |
Hoffmann La Roche |
COMBINATION OF A PARTICULAR BRAF INHIBITOR (PARADOX SWITCH) AND A PD-1 AXIS BINDING ANTAGONIST FOR USE IN THE TREATMENT OF CANCER.
|
|
MX2023014647A
(en)
|
2021-06-09 |
2024-01-31 |
Innate Pharma |
MULTI-SPECIFIC NKP46 BINDING PROTEINS.
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
|
EP4355778A1
(en)
|
2021-06-17 |
2024-04-24 |
Boehringer Ingelheim International GmbH |
Novel tri-specific binding molecules
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
AU2022295067A1
(en)
|
2021-06-18 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
|
WO2022268740A1
(en)
|
2021-06-21 |
2022-12-29 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
|
US20240294626A1
(en)
|
2021-06-22 |
2024-09-05 |
Novartis Ag |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
|
WO2022272128A1
(en)
|
2021-06-24 |
2022-12-29 |
Erasca, Inc. |
Antibodies against egfr and their uses
|
|
AU2022297107B2
(en)
|
2021-06-25 |
2024-08-01 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
|
CR20240026A
(en)
|
2021-06-25 |
2024-03-14 |
Chugai Pharmaceutical Co Ltd |
Anti–ctla-4 antibody
|
|
US12448451B2
(en)
|
2021-06-25 |
2025-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CTLA-4 antibody and use thereof
|
|
US20240343811A1
(en)
|
2021-06-29 |
2024-10-17 |
Shandong Simcere Biopharmacutical Co., Ltd. |
Cd16 antibody and use thereof
|
|
TW202309078A
(en)
|
2021-07-02 |
2023-03-01 |
美商建南德克公司 |
Methods and compositions for treating cancer
|
|
TW202320857A
(en)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
Linkers, drug linkers and conjugates thereof and methods of using the same
|
|
WO2023281120A1
(en)
|
2021-07-09 |
2023-01-12 |
Luxembourg Institute Of Health (Lih) |
Dimeric protein complexes and uses thereof
|
|
JP2024529339A
(en)
|
2021-07-13 |
2024-08-06 |
ジェネンテック， インコーポレイテッド |
Multivariate model for predicting cytokine release syndrome
|
|
CR20240074A
(en)
|
2021-07-14 |
2024-03-08 |
Genentech Inc |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
MX2024000501A
(en)
|
2021-07-14 |
2024-01-31 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Antigen-binding molecule specifically binding to hgfr and eger, and pharmaceutical use thereof.
|
|
EP4373851A2
(en)
|
2021-07-19 |
2024-05-29 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
JP2024526880A
(en)
|
2021-07-22 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
Brain targeting compositions and methods of use thereof
|
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
|
EP4377347A1
(en)
|
2021-07-27 |
2024-06-05 |
MorphoSys AG |
Combinations of antigen binding molecules
|
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
|
JP2024528217A
(en)
|
2021-08-03 |
2024-07-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Bispecific antibodies and methods of use
|
|
CN117897409A
(en)
|
2021-08-13 |
2024-04-16 |
基因泰克公司 |
Administration of anti-tryptase antibodies
|
|
JP2024534787A
(en)
|
2021-08-16 |
2024-09-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Novel IL27 receptor agonists and methods of use thereof
|
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
WO2023028591A1
(en)
|
2021-08-27 |
2023-03-02 |
Genentech, Inc. |
Methods of treating tau pathologies
|
|
JP2024534853A
(en)
|
2021-08-30 |
2024-09-26 |
ジェネンテック， インコーポレイテッド |
Anti-polybiquitin multispecific antibody
|
|
CN113603775B
(en)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
Anti-human interleukin-33 monoclonal antibody and application thereof
|
|
CN113683694B
(en)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
Anti-human TSLP monoclonal antibody and application thereof
|
|
AU2022338208A1
(en)
|
2021-09-06 |
2024-03-21 |
Genmab A/S |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
|
US20250223376A1
(en)
|
2021-09-20 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20240270874A1
(en)
|
2021-09-23 |
2024-08-15 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-klb antibodies and uses
|
|
CN118562019A
(en)
*
|
2021-09-30 |
2024-08-30 |
宁波三生生物科技股份有限公司 |
Recombinant follicle-stimulating hormone fusion protein
|
|
CN117916273A
(en)
|
2021-09-30 |
2024-04-19 |
江苏恒瑞医药股份有限公司 |
Anti-IL 23 antibody fusion proteins and uses
|
|
JPWO2023058723A1
(en)
|
2021-10-08 |
2023-04-13 |
|
|
|
CN118414353A
(en)
|
2021-10-08 |
2024-07-30 |
根马布股份公司 |
Antibodies that bind to CD30 and CD3
|
|
CN118215674A
(en)
|
2021-10-14 |
2024-06-18 |
豪夫迈·罗氏有限公司 |
Novel interleukin-7 immunoconjugate
|
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
TW202323281A
(en)
|
2021-10-14 |
2023-06-16 |
美商泰尼歐生物公司 |
Mesothelin binding proteins and uses thereof
|
|
CA3234162A1
(en)
|
2021-10-15 |
2023-04-20 |
Michele Fiscella |
Antibodies and methods of using thereof
|
|
JP2024539139A
(en)
|
2021-10-20 |
2024-10-28 |
シンセカイン インコーポレイテッド |
Heterodimeric FC cytokines and uses thereof
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
CN118119642A
(en)
|
2021-10-28 |
2024-05-31 |
诺华股份有限公司 |
Engineered Fc variants
|
|
EP4430072A1
(en)
|
2021-11-10 |
2024-09-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
EP4430079A1
(en)
|
2021-11-11 |
2024-09-18 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
IL312692A
(en)
|
2021-11-16 |
2024-07-01 |
Genentech Inc |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4437344A1
(en)
|
2021-11-25 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Quantification of low amounts of antibody sideproducts
|
|
CN118284625A
(en)
|
2021-11-26 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
Combination therapy of anti-TYRP1/anti-CD3 bispecific antibody and TYRP1-specific antibody
|
|
JPWO2023100829A1
(en)
|
2021-11-30 |
2023-06-08 |
|
|
|
EP4442274A4
(en)
|
2021-12-01 |
2025-12-24 |
Chugai Pharmaceutical Co Ltd |
METHOD FOR PRODUCING AN ANTIBODY-CONTAINING FORMULATION
|
|
JP2024541668A
(en)
|
2021-12-03 |
2024-11-08 |
山▲東▼先声生物制▲薬▼有限公司 |
Anti-BCMA nanobody and its applications
|
|
AR127887A1
(en)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
ANTIBODIES THAT BIND CD3 AND PLAP
|
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
|
JP2024547020A
(en)
|
2021-12-17 |
2024-12-26 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
Anti-OX40 antibodies, multispecific antibodies and methods of use thereof
|
|
CR20240246A
(en)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
AGONIST ANTI-LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES THAT INCLUDE THEM
|
|
CN118401674A
(en)
|
2021-12-21 |
2024-07-26 |
豪夫迈·罗氏有限公司 |
Methods for determining hydrolytic activity
|
|
JP2025500952A
(en)
|
2021-12-23 |
2025-01-15 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
Anti-DLL3 antibodies, antibody-drug conjugates thereof and pharmaceutical uses thereof
|
|
US20250145705A1
(en)
|
2021-12-31 |
2025-05-08 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Gprc5d antibody and application thereof
|
|
WO2023135198A1
(en)
|
2022-01-12 |
2023-07-20 |
Vib Vzw |
Human ntcp binders for therapeutic use and liver-specific targeted delivery
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
AR128330A1
(en)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
CHEMICAL DEGRADATION INDUCERS CONJUGATED WITH ANTIBODY AND METHODS OF THESE
|
|
AR128331A1
(en)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
CHEMICAL DEGRADATION INDUCTORS CONJUGATED WITH ANTIBODIES AND METHODS OF THESE
|
|
EP4469083A1
(en)
|
2022-01-28 |
2024-12-04 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
KR20240135663A
(en)
|
2022-01-28 |
2024-09-11 |
젠맵 에이/에스 |
Bispecific antibodies to CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
|
JP2025505611A
(en)
|
2022-02-07 |
2025-02-28 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
Antigen-binding molecule that specifically binds to PSMA and CD3 and its medical uses
|
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
EP4477674A1
(en)
|
2022-02-09 |
2024-12-18 |
Daiichi Sankyo Company, Limited |
Environmentally responsive masked antibody and use thereof
|
|
WO2023151661A1
(en)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
Immunoconjugate and use thereof
|
|
US20240117030A1
(en)
|
2022-03-03 |
2024-04-11 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
|
US20250205350A1
(en)
|
2022-03-10 |
2025-06-26 |
Vivasor, Inc. |
Antibody-Drug Conjugates and Uses Thereof
|
|
CN119173530A
(en)
|
2022-03-11 |
2024-12-20 |
詹森药业有限公司 |
Multispecific antibodies and their uses
|
|
KR20240156640A
(en)
|
2022-03-11 |
2024-10-30 |
얀센 파마슈티카 엔브이 |
Multispecific antibodies and uses thereof
|
|
CA3254098A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
|
MX2024011128A
(en)
|
2022-03-14 |
2024-09-18 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Antigen-binding molecule specifically binding to gprc5d and cd3 and medical use thereof.
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
KR20240161968A
(en)
|
2022-03-16 |
2024-11-13 |
다이이찌 산쿄 가부시키가이샤 |
Combination of multi-specific molecules and immune checkpoint inhibitors
|
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
CN118974096A
(en)
|
2022-03-25 |
2024-11-15 |
上海复宏汉霖生物技术股份有限公司 |
Anti-MSLN antibodies and methods of use
|
|
AR128876A1
(en)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
ENHANCED FOLR1 PROTEASE ACTIVATABLE T LYMPHOCYTE BISPECIFIC ANTIBODIES
|
|
IL315770A
(en)
|
2022-04-01 |
2024-11-01 |
Genentech Inc |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AR129062A1
(en)
|
2022-04-13 |
2024-07-10 |
Genentech Inc |
PHARMACEUTICAL COMPOSITIONS OF THERAPEUTIC PROTEINS AND METHODS OF USE
|
|
CN119013300A
(en)
|
2022-04-13 |
2024-11-22 |
豪夫迈·罗氏有限公司 |
Pharmaceutical compositions of anti-CD 20/anti-CD 3 bispecific antibodies and methods of use
|
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
CA3255838A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
|
JP7544986B2
(en)
|
2022-04-26 |
2024-09-03 |
中外製薬株式会社 |
Syringe with built-in filter containing pharmaceutical preparation
|
|
CN119137157A
(en)
|
2022-05-03 |
2024-12-13 |
基因泰克公司 |
Anti-Ly6E antibodies, immunoconjugates and uses thereof
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20250340668A1
(en)
|
2022-05-11 |
2025-11-06 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
|
AU2023269545A1
(en)
|
2022-05-12 |
2024-11-14 |
BioNTech SE |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CA3257348A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
JP2025517572A
(en)
|
2022-06-03 |
2025-06-05 |
エフ． ホフマン－ラ ロシュ アーゲー |
Improved Producer Cells
|
|
CN119654338A
(en)
|
2022-06-04 |
2025-03-18 |
再生元制药公司 |
Interleukin-2 protein and its use
|
|
EP4538294A1
(en)
|
2022-06-06 |
2025-04-16 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Multi-specific antibody targeting bcma, gprc5d and t cells and application thereof
|
|
WO2023246885A1
(en)
|
2022-06-23 |
2023-12-28 |
江苏恒瑞医药股份有限公司 |
Antigen-binding molecule specifically binding to dll3 and cd3, and pharmaceutical use thereof
|
|
JP2025523020A
(en)
|
2022-07-13 |
2025-07-17 |
ジェネンテック， インコーポレイテッド |
Administration for Treatment with Anti-FcRH5/Anti-CD3 Bispecific Antibody
|
|
JP2025523031A
(en)
|
2022-07-15 |
2025-07-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Binding Molecules for the Treatment of Cancer
|
|
IL318252A
(en)
|
2022-07-19 |
2025-03-01 |
Genentech Inc |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AR129991A1
(en)
|
2022-07-22 |
2024-10-23 |
Bristol Myers Squibb Co |
ANTIBODIES THAT BIND HUMAN PAD4 AND THEIR USES
|
|
AR129995A1
(en)
|
2022-07-22 |
2024-10-23 |
Genentech Inc |
ANTI-STEAP1 ANTIGEN BINDING MOLECULES AND THEIR USES
|
|
AU2023312905A1
(en)
|
2022-07-27 |
2025-01-16 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
JP2025528752A
(en)
|
2022-07-29 |
2025-09-02 |
アレクトル エルエルシー |
Transferrin receptor antigen-binding domain and methods of use thereof
|
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
EP4565597A2
(en)
|
2022-08-03 |
2025-06-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
AU2023318755A1
(en)
|
2022-08-03 |
2025-02-13 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
CN119546645A
(en)
|
2022-08-05 |
2025-02-28 |
江苏恒瑞医药股份有限公司 |
Antigen binding molecules specifically binding to GUCY2C and CD3 and their medical uses
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
KR20250048583A
(en)
|
2022-08-18 |
2025-04-09 |
리제너론 파아마슈티컬스, 인크. |
Interferon precursor protein and uses thereof
|
|
CN120153254A
(en)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
Bladder cancer treatment and diagnosis
|
|
WO2024052922A1
(en)
|
2022-09-11 |
2024-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-klk4 antibodies and uses thereof
|
|
JP2025535203A
(en)
|
2022-09-15 |
2025-10-23 |
ボイジャー セラピューティクス インコーポレイテッド |
Tau-binding compounds
|
|
KR20250067128A
(en)
|
2022-09-15 |
2025-05-14 |
아비디큐어 아이피 비.브이. |
Multispecific antigen binding proteins for tumor-targeting of NK cells and their uses
|
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
JP2025533849A
(en)
|
2022-10-07 |
2025-10-09 |
ジェネンテック， インコーポレイテッド |
Methods of treating cancer with anti-C-C motif chemokine receptor 8 (CCR8) antibodies
|
|
TW202430211A
(en)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Combination therapy of a gprc5d tcb and imids
|
|
TW202423969A
(en)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
|
TW202423970A
(en)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
CN115724975A
(en)
|
2022-10-20 |
2023-03-03 |
江苏荃信生物医药股份有限公司 |
Human interleukin 36receptor monoclonal antibody and application thereof
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
WO2024094017A1
(en)
|
2022-11-01 |
2024-05-10 |
上海齐鲁制药研究中心有限公司 |
Bispecific antibody for glypican-3 and use thereof
|
|
JP2025537529A
(en)
|
2022-11-02 |
2025-11-18 |
ジェンマブ エー／エス |
Bispecific antibodies against CD3 and CD20 for treating Richter's syndrome
|
|
CN120152989A
(en)
|
2022-11-03 |
2025-06-13 |
豪夫迈·罗氏有限公司 |
Combination therapy of anti-CD19/anti-CD28 bispecific antibodies
|
|
JP2025537197A
(en)
|
2022-11-08 |
2025-11-14 |
ジェネンテック， インコーポレイテッド |
Compositions and methods for treating childhood-onset idiopathic nephrotic syndrome
|
|
JP2025539040A
(en)
|
2022-11-10 |
2025-12-03 |
イムビア インク |
Cytotoxic bispecific antibodies that bind DR5 and MUC16 and uses thereof
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
EP4619427A1
(en)
|
2022-11-15 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Recombinant binding proteins with activatable effector domain
|
|
JP2025539760A
(en)
|
2022-11-15 |
2025-12-09 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
antigen binding molecule
|
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
|
CN120225684A
(en)
|
2022-11-23 |
2025-06-27 |
豪夫迈·罗氏有限公司 |
Methods for increasing expression of recombinant proteins
|
|
CN120265651A
(en)
|
2022-11-25 |
2025-07-04 |
中外制药株式会社 |
Methods for producing proteins
|
|
WO2024114676A1
(en)
|
2022-11-29 |
2024-06-06 |
江苏恒瑞医药股份有限公司 |
Cldn18.2/4-1bb binding protein and medical use thereof
|
|
EP4631974A1
(en)
|
2022-12-08 |
2025-10-15 |
Nanjing Vazyme Biotech Co., Ltd. |
Antibody specifically binding to rsv
|
|
EP4634397A1
(en)
|
2022-12-12 |
2025-10-22 |
Genentech Inc. |
Optimizing polypeptide sialic acid content
|
|
EP4385999A1
(en)
|
2022-12-14 |
2024-06-19 |
ModiQuest B.V. |
Antibodies
|
|
JP2025541200A
(en)
|
2022-12-15 |
2025-12-18 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Combination Therapies for Cancer Treatment
|
|
EP4634220A2
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
EP4638729A1
(en)
|
2022-12-23 |
2025-10-29 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
AU2024207469A1
(en)
|
2023-01-13 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2024151978A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
IL321951A
(en)
|
2023-01-18 |
2025-09-01 |
Genentech Inc |
Multispecific antibodies and uses thereof
|
|
WO2024153725A1
(en)
|
2023-01-20 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
|
EP4655315A1
(en)
|
2023-01-25 |
2025-12-03 |
F. Hoffmann-La Roche AG |
Payload-bearing multispecific antibodies
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
TW202436339A
(en)
|
2023-01-31 |
2024-09-16 |
瑞士商赫孚孟拉羅股份公司 |
Use for treating cancer selected from non-small cell lung cancer or triple negative breast cancer
|
|
WO2024165454A1
(en)
|
2023-02-06 |
2024-08-15 |
F. Hoffmann-La Roche Ag |
Combination therapy and uses thereof
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2024175031A1
(en)
|
2023-02-21 |
2024-08-29 |
江苏恒瑞医药股份有限公司 |
Il-36r binding protein and medicinal use thereof
|
|
EP4669669A1
(en)
|
2023-02-21 |
2025-12-31 |
Teneobio, Inc. |
C-KIT-BINDING PROTEINS, CHIMARY ANTIGEN RECEPTORS AND USES THEM
|
|
WO2024179470A1
(en)
|
2023-02-27 |
2024-09-06 |
苏州盛迪亚生物医药有限公司 |
Anti-dll3 antibody, and antibody-drug conjugate and pharmaceutical use thereof
|
|
KR20250166361A
(en)
|
2023-02-28 |
2025-11-27 |
리제너론 파아마슈티컬스, 인크. |
A multispecific molecule comprising a peptide-MHC complex comprising an MHC domain and an antigenic peptide and an immune cell antigen targeting moiety.
|
|
KR20250156759A
(en)
|
2023-02-28 |
2025-11-03 |
리제너론 파아마슈티컬스, 인크. |
Multivalent antispike protein binding molecules and uses thereof
|
|
CN120826234A
(en)
|
2023-03-06 |
2025-10-21 |
豪夫迈·罗氏有限公司 |
Combination therapy of anti-EGFRvIII/anti-CD3 antibodies and tumor-targeted 4-1BB agonists
|
|
CN120858109A
(en)
|
2023-03-10 |
2025-10-28 |
基因泰克公司 |
Fusions with proteases and uses thereof
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
CN121263449A
(en)
|
2023-03-21 |
2026-01-02 |
拜格拉夫55公司 |
CD19/CD38 multispecific antibody
|
|
TW202446789A
(en)
|
2023-03-31 |
2024-12-01 |
美商建南德克公司 |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
EP4688841A1
(en)
|
2023-04-03 |
2026-02-11 |
F. Hoffmann-La Roche AG |
All-in-one agonistic antibodies
|
|
EP4688840A1
(en)
|
2023-04-03 |
2026-02-11 |
F. Hoffmann-La Roche AG |
Agonistic split antibodies
|
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024208898A1
(en)
|
2023-04-05 |
2024-10-10 |
Genmab A/S |
Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
|
|
EP4687996A1
(en)
|
2023-04-05 |
2026-02-11 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
EP4442275A1
(en)
|
2023-04-06 |
2024-10-09 |
ModiQuest B.V. |
Anti-type ii collagen antibodies
|
|
WO2024213040A1
(en)
|
2023-04-11 |
2024-10-17 |
浙江博锐生物制药有限公司 |
Anti-ror1 antibody and drug conjugate thereof
|
|
TW202504915A
(en)
|
2023-04-13 |
2025-02-01 |
丹麥商珍美寶股份有限公司 |
Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
|
|
JPWO2024214811A1
(en)
|
2023-04-14 |
2024-10-17 |
|
|
|
CN121263210A
(en)
|
2023-04-17 |
2026-01-02 |
沛科生物公司 |
Antibodies and antibody-drug conjugates, as well as their usage, synthesis processes, and intermediates
|
|
TW202448949A
(en)
|
2023-05-05 |
2024-12-16 |
美商建南德克公司 |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AU2024269754A1
(en)
|
2023-05-08 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
WO2024233926A1
(en)
|
2023-05-10 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
US20240376229A1
(en)
|
2023-05-12 |
2024-11-14 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor antagonists and uses thereof
|
|
CN121285385A
(en)
|
2023-05-12 |
2026-01-06 |
金麦安博股份有限公司 |
Antibodies capable of binding to OX40, variants thereof and uses thereof
|
|
WO2024238537A1
(en)
|
2023-05-16 |
2024-11-21 |
F. Hoffmann-La Roche Ag |
Pd-1 -regulated il-2 immunocytokine and uses thereof
|
|
AU2024275646A1
(en)
|
2023-05-24 |
2025-11-13 |
Mozart Therapeutics, Inc. |
Cd8-specific binding proteins and methods of using the same
|
|
WO2024246083A1
(en)
|
2023-06-01 |
2024-12-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies targeting bcma and cd28
|
|
AR132805A1
(en)
|
2023-06-01 |
2025-07-30 |
Hoffmann La Roche |
Immunostimulatory antigen-binding molecules that specifically bind to BCMA
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|
|
WO2024258785A1
(en)
|
2023-06-11 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
WO2024258870A2
(en)
|
2023-06-12 |
2024-12-19 |
Amgen Inc. |
Lymphotoxin beta receptor agonist binding proteins
|
|
WO2024256623A1
(en)
|
2023-06-16 |
2024-12-19 |
Heidelberg Immunotherapeutics Gmbh |
Novel anti-hsv antibody
|
|
AU2024311339A1
(en)
|
2023-06-21 |
2026-01-08 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|
|
CN121443309A
(en)
|
2023-06-22 |
2026-01-30 |
基因泰克公司 |
Treatment of multiple myeloma
|
|
WO2024263761A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2025006529A1
(en)
|
2023-06-27 |
2025-01-02 |
Amgen Inc. |
Charge pair mutations to enable correct heavy-light chain pairing
|
|
WO2025007037A1
(en)
|
2023-06-28 |
2025-01-02 |
Dragonfly Therapeutics, Inc. |
Variant il-2 proteins
|
|
AU2024306598A1
(en)
|
2023-06-30 |
2025-12-11 |
Genmab A/S |
Antibodies binding to fibroblast activation protein alpha and death receptor 4
|
|
WO2025010272A1
(en)
*
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|
|
US12319747B2
(en)
|
2023-07-03 |
2025-06-03 |
Medicovestor, Inc. |
Methods of using anti-SP17 immunotherapeutics
|
|
WO2025024265A1
(en)
|
2023-07-21 |
2025-01-30 |
Bristol-Myers Squibb Company |
Methods of assessing citrullination and activity of pad4 modulators
|
|
WO2025021838A1
(en)
|
2023-07-26 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
TW202521576A
(en)
|
2023-07-30 |
2025-06-01 |
美商健生生物科技公司 |
Molecules that bind to mutant calreticulin and uses thereof
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025032071A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
AU2024323186A1
(en)
|
2023-08-09 |
2026-01-15 |
F. Hoffmann-La Roche Ag |
Mono and multispecific anti-trem2 antibodies, methods and uses thereof
|
|
TW202521562A
(en)
|
2023-08-11 |
2025-06-01 |
美商默沙東有限責任公司 |
Monovalent interleukin 12 (il-12) heterodimeric fc proteins
|
|
WO2025036892A1
(en)
|
2023-08-14 |
2025-02-20 |
Morphosys Ag |
Cycat halfbody molecules comprising sterically occluding moieties
|
|
WO2025038668A1
(en)
|
2023-08-14 |
2025-02-20 |
Voro Therapeutics, Inc. |
Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
|
|
WO2025040567A1
(en)
|
2023-08-18 |
2025-02-27 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025042742A1
(en)
|
2023-08-18 |
2025-02-27 |
Bristol-Myers Squibb Company |
Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
|
|
TW202525845A
(en)
|
2023-08-23 |
2025-07-01 |
法商賽諾菲公司 |
Ctla-4-based lysosomal degraders and uses thereof
|
|
WO2025054500A2
(en)
|
2023-09-08 |
2025-03-13 |
Mlab Biosciences, Inc. |
Bifunctional proteins and uses thereof
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025059037A1
(en)
|
2023-09-11 |
2025-03-20 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
WO2025064885A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
|
|
WO2025064890A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
|
|
AR133909A1
(en)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTIBODY THAT BINDS TO C3bBb
|
|
AR133955A1
(en)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USE THEREOF
|
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
WO2025082777A1
(en)
|
2023-10-17 |
2025-04-24 |
Morphosys Ag |
Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
|
|
US12364777B2
(en)
|
2023-10-20 |
2025-07-22 |
Medicovestor, Inc. |
Homodimeric antibodies for use in treating cancers and methods of use
|
|
AR134267A1
(en)
|
2023-11-08 |
2025-12-17 |
Sanofi Sa |
CD25-BASED LYSOSOMAL DEGRADER AND ITS USES
|
|
TW202535956A
(en)
|
2023-11-10 |
2025-09-16 |
美商輝瑞大藥廠 |
ANTI-MIGIS-α ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AR134356A1
(en)
|
2023-11-17 |
2026-01-07 |
Genentech Inc |
MCL-1 INHIBITOR COMPOUNDS AND USE IN ANTIBODY-DRUG CONJUGATES
|
|
TW202540189A
(en)
|
2023-11-30 |
2025-10-16 |
德商生物新技術公司 |
Antibodies capable of binding to ox40 in combination therapy
|
|
WO2025113643A1
(en)
|
2023-12-01 |
2025-06-05 |
Gilead Sciences Inc. |
Anti-fap-light fusion protein and use thereof
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025125118A1
(en)
|
2023-12-11 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Protease activatable fc domain binding molecules
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025129010A1
(en)
|
2023-12-14 |
2025-06-19 |
Genentech, Inc. |
Methods of structure determination using antibodies
|
|
WO2025132503A1
(en)
|
2023-12-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to ceacam5
|
|
WO2025137086A1
(en)
|
2023-12-20 |
2025-06-26 |
Genentech, Inc. |
Reducing alpha-gal
|
|
WO2025137454A1
(en)
|
2023-12-21 |
2025-06-26 |
Amgen Inc. |
Stabilizing homodimer mutations for two cell heterodimer production
|
|
TW202542177A
(en)
|
2023-12-22 |
2025-11-01 |
瑞士商赫孚孟拉羅股份公司 |
Activatable fusion proteins and methods of use
|
|
US12121587B1
(en)
|
2023-12-26 |
2024-10-22 |
Medicovestor, Inc. |
Dimeric antibodies
|
|
US12116410B1
(en)
|
2023-12-26 |
2024-10-15 |
Medicovestor, Inc. |
Methods of manufacturing dimeric antibodies
|
|
WO2025147696A1
(en)
|
2024-01-05 |
2025-07-10 |
Resolve Therapeutics, Llc |
Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents
|
|
WO2025149661A1
(en)
|
2024-01-10 |
2025-07-17 |
Genmab A/S |
Slitrk6 binding agents, conjugates thereof and methods of using the same
|
|
WO2025149633A1
(en)
|
2024-01-12 |
2025-07-17 |
Laigo Bio B.V. |
Bispecific antigen binding proteins
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
US12240900B1
(en)
|
2024-02-02 |
2025-03-04 |
Medicovestor, Inc. |
Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
|
|
US12378314B1
(en)
|
2024-02-02 |
2025-08-05 |
Medicovestor, Inc. |
Proteins that bind folate receptor alpha including fully-human antibodies
|
|
US12258396B1
(en)
|
2024-02-02 |
2025-03-25 |
Medicovestor, Inc. |
Methods of using immunotherapeutics that bind folate receptor alpha
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025172924A1
(en)
|
2024-02-15 |
2025-08-21 |
Janssen Biotech, Inc. |
Anti-transferrin receptor compositions and methods thereof
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2025181189A1
(en)
|
2024-03-01 |
2025-09-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191137A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of trop2-specific antigen binding proteins and cytokines
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
US20250313641A1
(en)
|
2024-04-09 |
2025-10-09 |
Amgen Inc. |
Agonistic anti-il-2rbg heavy-chain antibodies
|
|
WO2025215060A1
(en)
|
2024-04-11 |
2025-10-16 |
F. Hoffmann-La Roche Ag |
Antibodies that specifically bind modified oligonucleotides
|
|
WO2025219504A1
(en)
|
2024-04-19 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
|
WO2025222129A2
(en)
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025233431A1
(en)
|
2024-05-07 |
2025-11-13 |
Immatics Biotechnologies Gmbh |
Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
|
|
WO2025233304A1
(en)
|
2024-05-08 |
2025-11-13 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025237931A1
(en)
|
2024-05-15 |
2025-11-20 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|
|
WO2025240670A2
(en)
|
2024-05-15 |
2025-11-20 |
Abalytics Oncology, Inc. |
Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
|
|
WO2025238135A2
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Antibody with binding specificity for il-11
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
WO2025250969A1
(en)
|
2024-05-31 |
2025-12-04 |
Vertex Pharmaceuticals Incorporated |
Anti-cd74 antibodies, conjugates and uses thereof
|
|
WO2025255340A2
(en)
|
2024-06-05 |
2025-12-11 |
Genzyme Corporation |
BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
|
|
WO2025253337A2
(en)
|
2024-06-05 |
2025-12-11 |
Sanofi |
Monospecific and bispecific tau binding proteins and compositions thereof
|
|
US20250376536A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Multispecific anti-cd40 / anti-fap antibodies and uses thereof
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
US20250376524A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
WO2025259718A2
(en)
|
2024-06-11 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
WO2025257181A1
(en)
|
2024-06-11 |
2025-12-18 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies targeting trans-active response dna-binding protein-43 (tdp-43)
|
|
WO2025259871A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
CN121135878A
(en)
|
2024-06-14 |
2025-12-16 |
康诺亚生物医药科技（成都）有限公司 |
Bispecific antibodies against OX40L and IL-13 and uses thereof
|
|
WO2025264572A1
(en)
|
2024-06-17 |
2025-12-26 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
|
WO2025261943A1
(en)
|
2024-06-18 |
2025-12-26 |
F. Hoffmann-La Roche Ag |
Anti-cancer combinations comprising mosperafenib and folfox or folfiri
|
|
WO2026006162A2
(en)
|
2024-06-24 |
2026-01-02 |
Genentech, Inc. |
B vitamin modulation
|
|
WO2026003224A2
(en)
|
2024-06-26 |
2026-01-02 |
Iomx Therapeutics Ag |
Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
|
|
WO2026011013A1
(en)
|
2024-07-02 |
2026-01-08 |
Epibiologics, Inc. |
Binding agents and uses thereof
|
|
WO2026025058A1
(en)
|
2024-07-25 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Aav viral particles retargeted to egfr-expressing cancer cells
|